# Patent

## Title
Compositions and methods for inhibiting expression of CD45 gene

## Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. application Ser. No. 12/867,230, now U.S. Pat. No. 8,288,525, which is a National Stage Application of International Application No. PCT/US2009/033931, filed on Feb. 12, 2009, and to U.S. application Ser. No. 61/028,162, filed on Feb. 12, 2008.


GOVERNMENT SUPPORT
This invention was made with government support under HDTRA1-07-C-0082 awarded by the Defense/Defense Threat Reduction Agency, and HHSN266200600012C awarded by the Department of Health and Human Services/NIH/NAIAD. The government has certain rights in the invention.


SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Aug. 5, 2010, is named 21745US_CRF_sequencelisting.txt and is 126,484 bytes in size.
FIELD OF THE INVENTION
This invention relates to double-stranded ribonucleic acid (dsRNA), and its use in mediating RNA interference to inhibit the expression of the CD45 gene and the use of the dsRNA to treat infectious diseases and autoimmune disease.
BACKGROUND OF THE INVENTION
CD45 is a hematopoietic cell-specific transmembrane protein tyrosine phosphatase essential for T and B cell antigen receptor-mediated signaling and also plays a important role in cytokine receptor signaling, chemokine and cytokine response and apoptosis regulation in multiple different leukocyte cell subsets (T cells, B cells, NK cells, myeloid cells, granulocytes, and dendritic cells). CD45 constitutes nearly 10% of T and B cell surface protein. The protein includes a large extracellular domain, and a phosphatase containing cytosolic domain. CD45 may act as both a positive and negative regulator depending on the nature of the stimulus and the cell type involved. CD45 RNA transcripts are alternatively spliced at the N-terminus, which results in extracellular domains of various sizes. The protein controls the activity of Src-family kinases, which if left unregulated, can cause cancer and autoimmunity. Mice and humans lacking CD45 expression have been shown to be immunodeficient.
Multiple human or rodent mutations that result in altered CD45 expression or functional activity are associated with distinct malignancies, including autoimmunity, immunodeficiency, overt activation of T cells, susceptibility to infection, type I or type II associated immune disorders, and haemotologic malignancies (reviewed in Tchilian and Beverly, Trends in Immunology, 2006).
Double-stranded RNA molecules (dsRNA) have been shown to block gene expression in a highly conserved regulatory mechanism known as RNA interference (RNAi). WO 99/32619 (Fire et al.) discloses the use of a dsRNA of at least 25 nucleotides in length to inhibit the expression of the unc-22 gene in C. elegans. dsRNA has also been shown to degrade target RNA in other organisms, including plants (see, e.g., WO 99/53050, Waterhouse et al.; and WO 99/61631, Heifetz et al.), Drosophila (see, e.g., Yang, D., et al., Curr. Biol. (2000) 10:1191-1200), and mammals (see WO 00/44895, Limmer; and DE 101 00 586.5, Kreutzer et al.).
SUMMARY OF THE INVENTION
The invention provides double-stranded ribonucleic acid (dsRNA), as well as compositions and methods for inhibiting the expression of the CD45 gene in a cell or mammal using such dsRNA. The invention also provides compositions and methods for treating pathological conditions and diseases caused by the expression of the CD45 gene, such as infectious disease and autoimmune disease. The dsRNA featured in the invention includes an RNA strand (the antisense strand) having a region which is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and which is substantially complementary or fully complementary to the corresponding region of an mRNA transcript of the CD45 gene.
In one aspect, the invention features, double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of the CD45 gene. The dsRNA includes at least two sequences that are complementary, e.g., substantially or fully complementary, to each other. The dsRNA includes a sense strand including a first sequence and an antisense strand including a second sequence. The antisense strand includes a nucleotide sequence which is substantially or fully complementary to the corresponding region of an mRNA encoding CD45, and the region of complementarity is less than 30 nucleotides in length, generally 19-24 nucleotides in length, e.g., 19 to 21 nucleotides in length. In some embodiments, the dsRNA is from about 10 to about 15 nucleotides, and in other embodiments the dsRNA is from about 25 to about 30 nucleotides in length. In another embodiment, the dsRNA is at least 15 nucleotides in length. The dsRNA, upon contacting with a cell expressing the CD45, e.g., in an assay described herein, e.g., in a P388D1 cell assay as described herein (or an assay based on a cell with similar properties), inhibits the expression of the CD45 gene by at least 20% or 25%, and preferably by at least 35%, or preferably by at least 40%. In one embodiment, the CD45 dsRNA is formulated in a stable nucleic acid particle (SNALP).
The dsRNA molecules featured in the invention include dsRNAs that cleave a CD45 mRNA in a target sequence selected from the group consisting of SEQ ID NOs:97-144. The dsRNAs featured herein also include dsRNAs having a first sequence selected from the group consisting of the sense sequences of Tables 2, 4 and 5, and a second sequence selected from the group consisting of the antisense sequences of Tables 2, 4 and 5. The dsRNA molecules featured in the invention can include naturally occurring nucleotides or can included at least one modified nucleotide, such as a 2′-O-methyl modified nucleotide, a nucleotide including a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group. Alternatively, the modified nucleotide may be chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide. Generally, the first sequence of the dsRNA is selected from the group consisting of the sense sequences of Tables 2, 4 and 5, and the second sequence is selected from the group consisting of the antisense sequences of Tables 2, 4 and 5.
In another aspect, the invention provides a cell including a dsRNA targeting CD45. The cell can be a mammalian cell, such as a human cell.
In another aspect, the invention features a pharmaceutical composition containing a dsRNA, such as a dsRNA described herein, e.g., in Tables 2, 4 and 5, and a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutical composition does not include another agent that silences gene expression. In another embodiment, the pharmaceutical composition does not include another dsRNA, e.g., a dsRNA of a length or overhang structure described herein. In another embodiment, the pharamaceutical composition consists of or consists essentially of the subject dsRNA. In another embodiment, the pharmaceutical composition includes more than one dsRNA. In yet other embodiments, the pharmaceutical composition includes more than one but not more than 2, 3 or 4 dsRNAs.
In another aspect, the invention provides a method for inhibiting the expression of the CD45 gene in a cell, including the following steps:

    
    
        (a) introducing into the cell a double-stranded ribonucleic acid (dsRNA), e.g., a dsRNA described herein, e.g., a dsRNA that cleaves a CD45 mRNA in a target sequence selected from the group consisting of SEQ ID NOs:97-144, wherein the dsRNA includes at least two sequences that are complementary, e.g., substantially or fully complementary, to each other. The dsRNA includes a sense strand including a first sequence and an antisense strand including a second sequence. The antisense strand includes a region of complementarity which is substantially or fully complementary to the corresponding region of an mRNA encoding CD45, and wherein the region of complementarity is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and preferably, wherein the dsRNA, upon contact with a cell expressing the CD45, inhibits expression of the CD45 gene by at least 20%, at least 25%, or at least 40%; and
        (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the CD45 gene, thereby inhibiting expression of the CD45 gene in the cell.
    
    


In another aspect, the invention provides methods for treating, preventing or managing infectious disease by administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of one or more of the CD45 dsRNAs featured in the invention.
In another aspect, the invention provides methods for treating, preventing or managing autoimmune disease, including administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of one or more of the CD45 dsRNAs featured in the invention.
In another aspect, the invention provides methods for treating, preventing or managing inflammation, including administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of one or more of the CD45 dsRNAs featured in the invention.
In another aspect, the invention provides methods for treating, preventing or managing a viral infection, including administering to a patient in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of one or more of the CD45 dsRNAs featured in the invention.
In another aspect, the invention provides vectors for inhibiting the expression of the CD45 gene in a cell, including a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of one of the dsRNAs featured in the invention.
In another aspect, the invention provides a cell including a vector for inhibiting the expression of the CD45 gene in a cell. The vector includes a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of one of the CD45 dsRNAs featured in the invention.



BRIEF DESCRIPTION OF THE FIGURES
FIGS. 1A and 1B are graphs showing that a lipid-formulated dsRNA targeting CD45 delivered to mice intraperitoneally inhibited protein expression of CD45 in vivo in peritoneal macrophages as compared to an irreleveant similarly formulated dsRNA targeting GFP. FIG. 1A demonstrates reduction in CD45 protein expression following a single injection with 10 mg/kg formulated CD45 siRNA as compared to saline or irrelevant siRNA. FIG. 1B shows two independent dose response experiments demonstrating that substantial reduction in CD45 expression is seen in vivo following a single injection of 0.6-15 mg/kg formulated CD45 siRNA relative to irrelevant siRNA.
FIG. 2 is a bar graph showing in vitro RNAi-mediated silencing of CD45 in primary mouse bone-marrow derived monocytes using a lipodoid formulation.
FIG. 3 is a graph showing that genetically modified mice expressing different levels of CD45 are protected from 30,000×LD50 Ebola-Zaire virus challenge.
FIG. 4 is a bar graph showing in vitro RNAi-mediated silencing of CD45 in KG1, a human leukemia cell line using a lipodoid formulation.
FIGS. 5A and 5B illustrate the sequence of human CD45 cDNA (SEQ ID NO: 339) as recorded at GenBank Accession No. NM—002838.2 (version dated Jan. 13, 2008).
FIGS. 6A and 6B illustrate the sequence of mouse CD45 cDNA (SEQ ID NO: 340) as recorded at GenBank Accession No. NM—011210 (version dated Jan. 27, 2008).
FIGS. 7A and 7B illustrate the sequence of rhesus CD45 cDNA (SEQ ID NO: 341) as recorded at GenBank Accession No. XR—012672.1 (version dated Jun. 14, 2006).



DETAILED DESCRIPTION OF THE INVENTION
The invention provides double-stranded ribonucleic acid (dsRNA), as well as compositions and methods for inhibiting the expression of the CD45 gene in a cell or mammal using the dsRNA. The invention also provides compositions and methods for treating pathological conditions and diseases in a mammal caused by the expression of the CD45 gene using dsRNA. dsRNA directs the sequence-specific degradation of mRNA through a process known as RNA interference (RNAi). The process occurs in a wide variety of organisms, including mammals and other vertebrates.
The dsRNAs featured in the invention includes an RNA strand (the antisense strand) having a region which is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and is substantially or fully complementary to at least part of an mRNA transcript of the CD45 gene. The use of these dsRNAs enables the targeted degradation of mRNAs of genes that are implicated in autoimmunity and infectious disease in mammals. Using cell-based and animal assays, the present inventors have demonstrated that very low dosages of these dsRNA can specifically and efficiently mediate RNAi, resulting in significant inhibition of expression of the CD45 gene. Thus, the methods and compositions featured in the invention including these dsRNAs are useful for treating autoimmunity and infectious disease.
The following detailed description discloses how to make and use the dsRNA and compositions containing dsRNA to inhibit the expression of a target CD45 gene, as well as compositions and methods for treating diseases and disorders caused by the expression of CD45, such as an infectious disease or autoimmune disease. The pharmaceutical compositions featured in the invention include a dsRNA having an antisense strand having a region of complementarity which is less than 30 nucleotides in length, generally 19-24 nucleotides in length, and is substantially complementary to at least part of an RNA transcript of the CD45 gene, together with a pharmaceutically acceptable carrier.
Accordingly, certain aspects featured in the invention provide pharmaceutical compositions including a dsRNA targeting CD45 together with a pharmaceutically acceptable carrier, methods of using the compositions to inhibit expression of the CD45 gene, and methods of using the pharmaceutical compositions to treat diseases caused by expression of the CD45 gene.
I. Definitions
For convenience, the meaning of certain terms and phrases used in the specification, examples, and appended claims, are provided below. If there is an apparent discrepancy between the usage of a term in other parts of this specification and its definition provided in this section, the definition in this section shall prevail.
“G,” “C,” “A,” “T” and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine and uracil as a base, respectively. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, thymidine and uracil may be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide including a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide including inosine as its base may base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine may be replaced in the dsRNAs featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences including such replacement moieties are embodiments featured in the invention.
By “CD45” as used herein is meant a CD45 mRNA, protein, peptide, or polypeptide. The term “CD45” is also known in the art as PTPRC (protein tyrosine phosphatase, receptor type, C), B220, GP180, LCA, LY5, and T200. The sequence of human CD45 cDNA is recorded at GenBank Accession No. NM—002838.2 (version dated Jan. 13, 2008) (see FIGS. 5A and 5B). Other human CD45 sequences are recorded at GenBank Accession Nos. NM—080921.2, NM—080922.2, NM—080923.2, Y00062.1, Y00638.1, BC014239.2, BC017863.1, BC031525.1, BC121086.1, BC121087.1, BC127656.1, BC127657.1, AY429565.1, AY567999.1, AK130573.1, DA670254.1, DA948670.1, AY429566.1, and CR621867.1. Mouse CD45 mRNA sequences are found at GenBank Accession Nos. NM—011210.2, AK054056.1, AK088215.1, AK154893.1, AK171802.1, BC028512.1, EF101553.1, L36091.1, M11934.1, M14342.1, M14343.1, M15174.1, M17320.1, and M92933.1. Rhesus monkey CD45 mRNA sequence are found at GenBank Accession No. XR—012672.1.
As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of the CD45 gene, including mRNA that is a product of RNA processing of a primary transcription product.
As used herein, the term “strand including a sequence” refers to an oligonucleotide including a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.
The terms “complementary”, “fully complementary” and “substantially complementary” herein may be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of a dsRNA and a target sequence, as will be understood from the context of their use.
As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide including the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide including the second nucleotide sequence, as will be understood by the skilled person. Complimentary includes both fully complimentary and substantially complimentary states. Fully complimentary means comlimentarity at each nucleotide pair of to compared sequences, e.g., an antisence strand and the corresponding portion of a target mRNA. For substantial complementarity, such conditions can, for example, be stringent conditions, where stringent conditions may include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50° C. or 70° C. for 12-16 hours followed by washing. Other conditions, such as physiologically relevant conditions as may be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides. In other embodiments, substantial complimentarity can mean not more than 4, 3 or 2 mismatched base pairs upon hybridization, while retaining the ability to hybridize under the conditions most relevant to their ultimate application. Where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA including one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide includes a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, may yet be referred to as “fully complementary” for the purposes of the invention.
“Complementary” sequences, as used herein, may also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified nucleotides, in as far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs includes, but not limited to, G:U Wobble or Hoogstein base pairing.
As used herein, a polynucleotide which is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide which is substantially complementary to a contiguous portion of the mRNA of interest (e.g., encoding CD45). For example, a polynucleotide is complementary to at least a part of a CD45 mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding CD45.
The term “double-stranded RNA” or “dsRNA”, as used herein, refers to a ribonucleic acid molecule, or complex of ribonucleic acid molecules, having a duplex structure including two anti-parallel and substantially complementary, as defined above, nucleic acid strands. The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′ end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop”. Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′ end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker.” The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA. In addition to the duplex structure, a dsRNA may comprise one or more nucleotide overhangs. A dsRNA as used herein is also referred to as a “small inhibitory RNA” or “siRNA.”
As used herein, a “nucleotide overhang” refers to the unpaired nucleotide or nucleotides that protrude from the duplex structure of a dsRNA when a 3′-end of one strand of the dsRNA extends beyond the 5′-end of the other strand, or vice versa. “Blunt” or “blunt end” means that there are no unpaired nucleotides at that end of the dsRNA, i.e., no nucleotide overhang. A “blunt ended” dsRNA is a dsRNA that is double-stranded over its entire length, i.e., no nucleotide overhang at either end of the molecule.
The term “antisense strand” refers to the strand of a dsRNA which includes a region that is substantially complementary to the corresponding sequence of a target sequence. As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches may be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 6, 5, 4, 3, or 2 nucleotides of the 5′ and/or 3′ terminus.
The term “sense strand,” as used herein, refers to the strand of a dsRNA that includes a region that is substantially complementary to a region of the antisense strand.
The term “identity” is the relationship between two or more polynucleotide sequences, as determined by comparing the sequences. Identity also means the degree of sequence relatedness between polynucleotide sequences, as determined by the match between strings of such sequences. While there exist a number of methods to measure identity between two polynucleotide sequences, the term is well known to skilled artisans (see, e.g., Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press (1987); and Sequence Analysis Primer, Gribskov., M. and Devereux, J., eds., M. Stockton Press, New York (1991)). “Substantially identical,” as used herein, means there is a very high degree of homology (preferably 100% sequence identity) between the sense strand of the dsRNA and the corresponding part of the target gene. However, dsRNA having greater than 90% or 95% sequence identity may be used in the present invention, and thus sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence can be tolerated. Although 100% identity is typical, the dsRNA may contain single or multiple base-pair random mismatches between the RNA and the target gene.
As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle. A SNALP represents a vesicle of lipids coating a reduced aqueous interior comprising a nucleic acid such as an iRNA agent or a plasmid from which an iRNA agent is transcribed. SNALPs are described, e.g., in U.S. Patent Application Publication Nos. 20060240093, 20070135372, and U.S. Ser. No. 61/045,228 filed Apr. 15, 2008. These applications are hereby incorporated by reference.
“Introducing into a cell,” when referring to a dsRNA, means facilitating uptake or absorption into the cell, as is understood by those skilled in the art. Absorption or uptake of dsRNA can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. The meaning of this term is not limited to cells in vitro; a dsRNA may also be “introduced into a cell,” wherein the cell is part of a living organism. In such instance, introduction into the cell will include the delivery to the organism. For example, for in vivo delivery, dsRNA can be injected into a tissue site or administered systemically. In vivo delivery can also be by a beta-glucan delivery system, such as those described in U.S. Pat. Nos. 5,032,401 and 5,607,677, and U.S. Publication No. 2005/0281781. U.S. Pat. Nos. 5,032,401 and 5,607,677, and U.S. Publication No. 2005/0281781 are hereby incorporated by reference in their entirety. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection.
The terms “silence” and “inhibit the expression of,” “down-regulate the expression of,” “suppress the expression of,” and the like, in as far as they refer to the CD45 gene, herein refer to the at least partial suppression of the expression of the CD45 gene, as manifested by a reduction of the amount of CD45 mRNA, which may be isolated from a first cell or group of cells in which the CD45 gene is transcribed, and which has or have been treated such that the expression of the CD45 gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has or have not been so treated (control cells). The degree of inhibition is usually expressed in terms of




  
    
      
        
          (
          
            mRNA
            ⁢
            
              
            
            ⁢
            in
            ⁢
            
              
            
            ⁢
            control
            ⁢
            
              
            
            ⁢
            cells
          
          )
        
        -
        
          (
          
            mRNA
            ⁢
            
              
            
            ⁢
            in
            ⁢
            
              
            
            ⁢
            treated
            ⁢
            
              
            
            ⁢
            cells
          
          )
        
      
      
        (
        
          mRNA
          ⁢
          
            
          
          ⁢
          in
          ⁢
          
            
          
          ⁢
          control
          ⁢
          
            
          
          ⁢
          cells
        
        )
      
    
    ·
    100
  
  ⁢
  %




Alternatively, the degree of inhibition may be given in terms of a reduction of a parameter that is functionally linked to CD45 gene expression, e.g. the amount of protein encoded by the CD45 gene which is present on the cell surface, or the number of cells displaying a certain phenotype, e.g apoptosis. In principle, CD45 gene silencing may be determined in any cell expressing the CD45, either constitutively or by genomic engineering, and by any appropriate assay. However, when a reference is needed in order to determine whether a given siRNA inhibits the expression of the CD45 gene by a certain degree and therefore is encompassed by the instant invention, the assays provided in the Examples below shall serve as such reference.
For example, in certain instances, expression of the CD45 gene is suppressed by at least about 20%, 25%, 30%, 35%, 40%, 45%, or 50% by administration of the double-stranded oligonucleotide featured in the invention. In one embodiment, the CD45 gene is suppressed by at least about 50%, 60%, or 70% by administration of the double-stranded oligonucleotide featured in the invention. In another embodiment, the CD45 gene is suppressed by at least about 75%, 80%, 90% or 95% by administration of the double-stranded oligonucleotide featured in the invention.
The terms “treat,” “treatment,” and the like, refer to relief from or alleviation of an infectious disease or an autoimmune disease. In the context of the present invention insofar as it relates to any of the other conditions recited herein below (e.g., a CD45-mediated condition other than an infectious disease or autoimmune disease), the terms “treat,” “treatment,” and the like mean to relieve or alleviate at least one symptom associated with such condition, or to slow or reverse the progression of such condition.
As used herein, the term “CD45-mediated condition or disease” and related terms and phrases refer to a condition or disorder characterized by inappropriate, e.g., greater than normal, CD45 activity. Inappropriate CD45 functional activity might arise as the result of CD45 expression in cells which normally do not express CD45 or increased CD45 expression (leading to, e.g., autoimmune disease). A CD45-mediated condition or disease may be completely or partially mediated by inappropriate CD45 functional activity. However, a CD45-mediated condition or disease is one in which modulation of CD45 results in some effect on the underlying condition or disorder (e.g., a CD45 inhibitor results in some improvement in patient well-being in at least some patients).
As used herein, the phrases “therapeutically effective amount” and “prophylactically effective amount” refer to an amount that provides a therapeutic benefit in the treatment, prevention, or management of an infectious disease or an overt symptom of infection, or an autoimmune disease. The specific amount that is therapeutically effective can be readily determined by ordinary medical practitioner, and may vary depending on factors known in the art, such as, e.g. the type of infection or autoimmune disease, the patient's history and age, the stage of the disease, and the administration of other agents.
As used herein, a “pharmaceutical composition” includes a pharmacologically effective amount of a dsRNA and a pharmaceutically acceptable carrier. As used herein, “pharmacologically effective amount,” “therapeutically effective amount” or simply “effective amount” refers to that amount of a RNA effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 25% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 25% reduction in that parameter.
The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
As used herein, a “transformed cell” is a cell into which a vector has been introduced from which a dsRNA molecule may be expressed.
II. Double-Stranded Ribonucleic Acid (dsRNA)
In one embodiment, the invention provides double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of the CD45 gene in a cell or mammal. The dsRNA includes an antisense strand including a region of complementarity which is complementary to the corresponding region of an mRNA formed in the expression of the CD45 gene, and wherein the region of complementarity is less than 30 nucleotides in length, generally 19-24 nucleotides in length. In another embodiment the dsRNA, upon contact with a cell expressing said CD45 gene, inhibits the expression of said CD45 gene, e.g., in an assay described herein, e.g., in a P388D1 cell assay (or an assay based on a similar cell) as described herein, by at least 20%, or preferably by at least 40%. The dsRNA includes two RNA strands that are sufficiently complementary to hybridize to form a duplex structure. The sense strand includes a region which is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. Generally, the duplex structure is between 15 and 30, more generally between 18 and 25, yet more generally between 19 and 24, and most generally between 21 and 23 base pairs in length. Similarly, the region of complementarity to the target sequence is between 15 and 30, more generally between 18 and 25, yet more generally between 19 and 24, and most generally between 19 and 21 nucleotides in length. In some embodiments, the dsRNA is between 10 and 15 nucleotides in length, and in other embodiments, the dsRNA is between 25 and 30 nucleotides in length. The dsRNA featured in the invention may further include one or more single-stranded nucleotide overhang(s).
The dsRNA can be synthesized by standard methods known in the art as further discussed below, e.g., by use of an automated DNA synthesizer, such as are commercially available from, for example, Biosearch, Applied Biosystems, Inc. In one embodiment, the CD45 gene is the human CD45 gene. In some embodiments, the antisense strand of the dsRNA includes a sense sequence from Tables 2, 4 and 5, and the sense strand of the dsRNA includes a sense sequence from Tables 2, 4 and 5.
In other embodiments, the dsRNA includes at least one nucleotide sequence selected from the groups of sequences provided in Tables 2, 4 and 5. In other embodiments, the dsRNA includes at least two sequences selected from this group, wherein one of the at least two sequences is complementary to another of the at least two sequences, and one of the at least two sequences is substantially complementary to a sequence of an mRNA generated in the expression of the CD45 gene. Generally, the dsRNA includes two oligonucleotides, wherein one oligonucleotide is described as a sense strand in Tables 2, 4, or 5, and the second oligonucleotide is described as an antisense strand in Tables 2, 4 or 5.
The skilled person is well aware that dsRNAs including a duplex structure of between 20 and 23, but specifically 21, base pairs have been identified as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer dsRNAs can be effective as well. In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in Tables 2, 4, or 5, the dsRNAs featured in the invention can include at least one strand of a length of minimally 21 nt. It can be reasonably expected that shorter dsRNAs including one of the sequences of Table 2, 4 or 5, minus only a few nucleotides on one or both ends may be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs including a partial sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides from one of the sequences of Table 2, 4 or 5, and differing in their ability to inhibit the expression of the CD45 gene in a FACS assay as described herein below by not more than 5, 10, 15, 20, 25, or 30% inhibition from a dsRNA including the full sequence, are contemplated by the invention.
In addition, the dsRNA agents provided in Tables 2, 4 and 5 identify sites in the CD45 mRNA that are susceptible to RNAi based cleavage. As such, the invention further includes dsRNAs that target within the sequence targeted by one of the agents featured in the present invention. As used herein, a second dsRNA is said to target within the sequence of a first dsRNA if the second dsRNA cleaves the message anywhere within the mRNA that is complementary to the antisense strand of the first dsRNA. Such a second agent will generally consist of at least 15 contiguous nucleotides from one of the sequences provided in Tables 2, 4 and 5 coupled to additional nucleotide sequences taken from the region contiguous to the selected sequence in the CD45 gene.
The dsRNA featured in the invention can contain one or more mismatches to the target sequence. In one embodiment, the dsRNA targeting CD45 contains no more than 3 mismatches. If the antisense strand of the dsRNA contains mismatches to a target sequence, it is preferable that the area of mismatch not be located in the center of the region of complementarity. If the antisense strand of the dsRNA contains mismatches to the target sequence, it is preferable that the mismatch be restricted to 5 nucleotides from either end, for example 5, 4, 3, 2, or 1 nucleotide from either the 5′ or 3′ end of the region of complementarity. For example, for a 23 nucleotide dsRNA strand which is complementary to a region of the CD45 gene, the dsRNA generally does not contain any mismatch within the central 13 nucleotides. The methods described within the invention can be used to determine whether a dsRNA containing a mismatch to a target sequence is effective in inhibiting the expression of the CD45 gene. Consideration of the efficacy of dsRNAs with mismatches in inhibiting expression of the CD45 gene is important, especially if the particular region of complementarity in the CD45 gene is known to have polymorphic sequence variation within the population.
In one embodiment, at least one end of the dsRNA has a single-stranded nucleotide overhang of 1 to 4, generally 1 or 2 nucleotides. dsRNAs having at least one nucleotide overhang have unexpectedly superior inhibitory properties than their blunt-ended counterparts. In one embodiment the presence of only one nucleotide overhang strengthens the interference activity of the dsRNA, without affecting its overall stability. dsRNA having only one overhang has proven particularly stable and effective in vivo, as well as in a variety of cells, cell culture mediums, blood, and serum. Generally, the single-stranded overhang is located at the 3′-terminal end of the antisense strand or, alternatively, at the 3′-terminal end of the sense strand. The dsRNA may also have a blunt end, generally located at the 5′-end of the antisense strand. Such dsRNAs have improved stability and inhibitory activity, thus allowing administration at low dosages, i.e., less than 5 mg/kg body weight of the recipient per day. In one embodiment, the antisense strand of the dsRNA has a 1-10 nucleotide overhang at the 3′ end and/or the 5′ end. In one embodiment, the sense strand of the dsRNA has a 1-10 nucleotide overhang at the 3′ end and/or the 5′ end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.
In yet another embodiment, the dsRNA is chemically modified to enhance stability. The nucleic acids featured in the invention may be synthesized and/or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry”, Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Specific examples of dsRNA compounds useful in this invention include dsRNAs containing modified backbones or no natural internucleoside linkages. As defined in this specification, dsRNAs having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified dsRNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.
Modified dsRNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those) having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, mixed salts and free acid forms are also included.
Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, each of which is herein incorporated by reference
Modified dsRNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or ore or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts.
Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, each of which is herein incorporated by reference.
In other dsRNA mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, a dsRNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of a dsRNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500.
Typical embodiments include dsRNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular—CH2—NH—CH2—, —CH2—N(CH3)—O—CH2—[known as a methylene (methylimino) or MMI backbone], —CH2—O—N(CH3)—CH2—, —CH2—N(CH3)—N(CH3)—CH2— and —N(CH3)—CH2—CH2—[wherein the native phosphodiester backbone is represented as —O—P—O—CH2—] of the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. Other suitable dsRNAs have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506.
Modified dsRNAs may also contain one or more substituted sugar moieties. Typical dsRNAs include one of the following at the 2′ position: OH; F; O—, S—, or N- alkyl; O—, S—, or N-alkenyl; O—, S—or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and alkynyl. Other dsRNAs include O[(CH2)nO]mCH3, O(CH2)nOCH3, O(CH2)nNH2, O(CH2)nCH3, O(CH2)nONH2, and O(CH2)nON[(CH2)nCH3)]2, where n and m are from 1 to about 10. Other typical dsRNAs include one of the following at the 2′ position: C1 to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3, ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an dsRNA, or a group for improving the pharmacodynamic properties of an dsRNA, and other substituents having similar properties. In one embodiment, the modification includes 2′-methoxyethoxy (2′-O—CH2CH2OCH3, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504), i.e., an alkoxy-alkoxy group. Another suitable modification includes 2′-dimethylaminooxyethoxy, i.e., a O(CH2)2ON(CH3)2 group, also known as 2′-DMAOE, as described in examples hereinbelow, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethylaminoethoxyethyl or 2′-DMAEOE), i.e., 2′-O—CH2—O—CH2—N(CH2)2, also described in examples hereinbelow.
Other suitable modifications include 2′-methoxy (2′-OCH3), 2′-aminopropoxy (2′-OCH2CH2CH2NH2) and 2′-fluoro (2′-F). Similar modifications may also be made at other positions on the dsRNA, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked dsRNAs and the 5′ position of 5′ terminal nucleotide. DsRNAs may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.
dsRNAs may also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, DsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., DsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are suitable base substitutions, particularly when combined with 2′-O-methoxyethyl sugar modifications.
Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos. 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, each of which is herein incorporated by reference, and U.S. Pat. No. 5,750,692, also herein incorporated by reference.
Another modification of the dsRNAs featured in the invention involves chemically linking to the dsRNA one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the dsRNA. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 199, 86, 6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994 4 1053-1060), a thioether, e.g., beryl-5-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-Hphosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937).
Representative U.S. patents that teach the preparation of such dsRNA conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, each of which is herein incorporated by reference.
It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within a dsRNA. The present invention also includes dsRNA compounds which are chimeric compounds. “Chimeric” dsRNA compounds or “chimeras,” in the context of this invention, are dsRNA compounds, particularly dsRNAs, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA compound. These dsRNAs typically contain at least one region wherein the dsRNA is modified so as to confer upon the dsRNA increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the dsRNA may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of dsRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter dsRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxydsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
In certain instances, the dsRNA may be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to dsRNAs in order to enhance the activity, cellular distribution or cellular uptake of the dsRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-5-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such dsRNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of dsRNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction may be performed either with the dsRNA still bound to the solid support or following cleavage of the dsRNA in solution phase. Purification of the dsRNA conjugate by HPLC typically affords the pure conjugate. The use of a cholesterol conjugate is particularly suitable since such a moiety can increase targeting vaginal epithelium cells, a site of CD45 expression expression.
Vector Encoded dsRNA Agents
The dsRNA featured in the invention can also be expressed from recombinant viral vectors intracellularly in vivo. The recombinant viral vectors featured in the invention comprise sequences encoding the dsRNA and any suitable promoter for expressing the dsRNA sequences. Suitable promoters include, for example, the U6 or H1 RNA pol III promoter sequences and the cytomegalovirus promoter. Selection of other suitable promoters is within the skill in the art. The recombinant viral vectors can also comprise inducible or regulatable promoters for expression of the dsRNA in a particular tissue or in a particular intracellular environment. The use of recombinant viral vectors to deliver dsRNA to cells in vivo is discussed in more detail below.
dsRNA featured in the invention can be expressed from a recombinant viral vector either as two separate, complementary RNA molecules, or as a single RNA molecule with two complementary regions.
Any viral vector capable of accepting the coding sequences for the dsRNA molecule(s) to be expressed can be used, for example vectors derived from adenovirus (AV); adeno-associated virus (AAV); retroviruses (e.g, lentiviruses (LV), Rhabdoviruses, murine leukemia virus); herpes virus, and the like. The tropism of viral vectors can be modified by pseudotyping the vectors with envelope proteins or other surface antigens from other viruses, or by substituting different viral capsid proteins, as appropriate.
For example, lentiviral vectors can be pseudotyped with surface proteins from vesicular stomatitis virus (VSV), rabies, Ebola, Mokola, and the like. AAV vectors can be made to target different cells by engineering the vectors to express different capsid protein serotypes. For example, an AAV vector expressing a serotype 2 capsid on a serotype 2 genome is called AAV 2/2. This serotype 2 capsid gene in the AAV 2/2 vector can be replaced by a serotype 5 capsid gene to produce an AAV 2/5 vector. Techniques for constructing AAV vectors which express different capsid protein serotypes are within the skill in the art; see, e.g., Rabinowitz J E et al. (2002), J Virol 76:791-801, the entire disclosure of which is herein incorporated by reference.
Selection of recombinant viral vectors suitable for use in the invention, methods for inserting nucleic acid sequences for expressing the dsRNA into the vector, and methods of delivering the viral vector to the cells of interest are within the skill in the art. See, for example, Dornburg R (1995), Gene Therap. 2: 301-310; Eglitis M A (1988), Biotechniques 6: 608-614; Miller A D (1990), Hum Gene Therap. 1: 5-14; Anderson W F (1998), Nature 392: 25-30; and Rubinson D A et al., Nat. Genet. 33: 401-406, the entire disclosures of which are herein incorporated by reference.
Typical viral vectors are those derived from AV and AAV. In one embodiment, the dsRNA featured in the invention is expressed as two separate, complementary single-stranded RNA molecules from a recombinant AAV vector including, for example, either the U6 or H1 RNA promoters, or the cytomegalovirus (CMV) promoter.
A suitable AV vector for expressing the dsRNA featured in the invention, a method for constructing the recombinant AV vector, and a method for delivering the vector into target cells, are described in Xia H et al. (2002), Nat. Biotech. 20: 1006-1010.
Suitable AAV vectors for expressing the dsRNA featured in the invention, methods for constructing the recombinant AV vector, and methods for delivering the vectors into target cells are described in Samulski R et al. (1987), J. Virol. 61: 3096-3101; Fisher K J et al. (1996), J. Virol, 70: 520-532; Samulski R et al. (1989), J. Virol. 63: 3822-3826; U.S. Pat. No. 5,252,479; U.S. Pat. No. 5,139,941; International Patent Application No. WO 94/13788; and International Patent Application No. WO 93/24641, the entire disclosures of which are herein incorporated by reference.
III. Pharmaceutical Compositions Including dsRNA
The invention provides pharmaceutical compositions including a dsRNA, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical composition including the dsRNA is useful for treating a disease or disorder associated with the expression or activity of the CD45 gene, such as pathological processes mediated by CD45 expression. Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for systemic administration via parenteral delivery.
The pharmaceutical compositions featured in the invention are administered in dosages sufficient to inhibit expression of the CD45 gene. The present inventors have found that, because of their improved efficiency, compositions including the dsRNA can be administered at surprisingly low dosages. Dosages of 0.6 mg or greater of dsRNA per kilogram body weight of recipient per day is sufficient to suppress expression of the CD45 gene by greater than 35%, with higher dosages capable of achieving 65% reduction in expression of the CD45 gene.
In general, a suitable dose of dsRNA will be in the range of 0.01 to 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of 0.02 to 50 mg per kilogram body weight per day. For example, the dsRNA can be administered at 0.01, 0.1, 0.05 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, or 50 mg/kg per single dose. The pharmaceutical composition may be administered once daily, or the dsRNA may be administered as two, three, or more sub-doses at appropriate intervals throughout the day or even using continuous infusion or delivery through a controlled release formulation. In that case, the dsRNA contained in each sub-dose must be correspondingly smaller in order to achieve the total daily dosage. The dosage unit can also be compounded for delivery over several days, e.g., using a conventional sustained release formulation which provides sustained release of the dsRNA over a several day period. Sustained release formulations are well known in the art and are particularly useful for vaginal delivery of agents, such as could be used with the dsRNAs featured in the invention. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose.
The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the individual dsRNAs encompassed by the invention can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein.
Advances in mouse genetics have generated a number of mouse models for the study of various human diseases, such as pathological processes mediated by CD45 expression. Such models are used for in vivo testing of dsRNA, as well as for determining a therapeutically effective dose.
The present invention also includes pharmaceutical compositions and formulations which include dsRNA targeting CD45. The pharmaceutical compositions may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (e.g., by a transdermal patch), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Administration may also be designed to result in preferential localization to particular tissues through local delivery, e.g., by direct intraarticular injection into joints, by rectal administration for direct delivery to the gut and intestines, by intravaginal administration for delivery to the cervix and vagina, by intravitreal administration for delivery to the eye. Parenteral administration includes intravenous, intraarterial, intraarticular, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, e.g., via an implanted device; or intracranial, e.g., by intrathecal or intraventricular administration.
Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Typical topical formulations include those in which the dsRNAs featured in the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Typical lipids and liposomes include neutral (e.g., dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g., dimyristoylphosphatidyl glycerol DMPG), and cationic (e.g., dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). DsRNAs featured the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, dsRNAs may be complexed to lipids, in particular to cationic lipids. Typical fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C1-10 alkyl ester (e.g., isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in U.S. patent application Ser. No. 09/315,298 filed May 20, 1999, which is incorporated herein by reference in its entirety.
In one embodiment, a dsRNA featured in the invention is fully encapsulated in the lipid formulation (e.g., to form a SPLP, pSPLP, SNALP, or other nucleic acid-lipid particle). As used herein, the term “SNALP” refers to a stable nucleic acid-lipid particle, including SPLP. As used herein, the term “SPLP” refers to a nucleic acid-lipid particle comprising plasmid DNA encapsulated within a lipid vesicle. SNALPs and SPLPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). SNALPs and SPLPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). SPLPs include “pSPLP,” which include. an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 00/03683. The particles of the present invention typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid-lipid particles of the present invention are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Pat. Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; and PCT Publication No. WO 96/40964.
In one embodiment, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1.
The cationic lipid may be, for example, N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), or a mixture thereof. The cationic lipid may comprise from about 20 mol % to about 50 mol % or about 40 mol % of the total lipid present in the particle.
The non-cationic lipid may be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE),16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid may be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol % if cholesterol is included, of the total lipid present in the particle.
The conjugated lipid that inhibits aggregation of particles may be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG-dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG-DAA conjugate may be, for example, a PEG-dilauryloxypropyl (Ci2), a PEG-dimyristyloxypropyl (Ci4), a PEG-dipalmityloxypropyl (Ci6), or a PEG-distearyloxypropyl (C]8). The conjugated lipid that prevents aggregation of particles may be from 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particle.
In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, e.g., about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.
In one embodiment, the lipidoid ND98.4HCl (MW 1487) (Formula I), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-siRNA nanoparticles (i.e., LNP01 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/mL; Cholesterol, 25 mg/mL, PEG-Ceramide C16, 100 mg/mL. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, e.g., 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous siRNA (e.g., in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-siRNA nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (e.g., 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, e.g., about pH 6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.




LNP01 formulations are described, e.g., in International Application Publication No. WO 2008/042973, which is hereby incorporated by reference.
Formulations prepared by either the standard or extrusion-free method can be characterized in similar manners. For example, formulations are typically characterized by visual inspection. They should be whitish translucent solutions free from aggregates or sediment. Particle size and particle size distribution of lipid-nanoparticles can be measured by light scattering using, for example, a Malvern Zetasizer Nano ZS (Malvern, USA). Particles should be about 20-300 nm, such as 40-100 nm in size. The particle size distribution should be unimodal. The total siRNA concentration in the formulation, as well as the entrapped fraction, is estimated using a dye exclusion assay. A sample of the formulated siRNA can be incubated with an RNA-binding dye, such as Ribogreen (Molecular Probes) in the presence or absence of a formulation disrupting surfactant, e.g., 0.5% Triton-X100. The total siRNA in the formulation can be determined by the signal from the sample containing the surfactant, relative to a standard curve. The entrapped fraction is determined by subtracting the “free” siRNA content (as measured by the signal in the absence of surfactant) from the total siRNA content. Percent entrapped siRNA is typically >85%. For SNALP formulation, the particle size is at least 30 nm, at least 40 nm, at least 50 nm, at least 60 nm, at least 70 nm, at least 80 nm, at least 90 nm, at least 100 nm, at least 110 nm, and at least 120 nm. The suitable range is typically about at least 50 nm to about at least 110 nm, about at least 60 nm to about at least 100 nm, or about at least 80 nm to about at least 90 nm.
Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Typical oral formulations are those in which dsRNAs featured in the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Typical surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Typical bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Typical fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Suitable combinations of penetration enhancers include, for example, fatty acids/salts in combination with bile acids/salts. One typical combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Typical complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in U.S. application. Ser. No. 08/886,829 (filed Jul. 1, 1997), Ser. No. 09/108,673 (filed Jul. 1, 1998), Ser. No. 09/256,515 (filed Feb. 23, 1999), Ser. No. 09/082,624 (filed May 21, 1998) and Ser. No. 09/315,298 (filed May 20, 1999), each of which is incorporated herein by reference in their entirety.
Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
Pharmaceutical compositions featured in the invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.
The pharmaceutical formulations featured in the invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
The compositions featured in the invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions featured in the invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.
In one embodiment, the pharmaceutical composition may be formulated and used as a foam. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions featured herein.
Emulsions
The compositions featured in the invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems including two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.
Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).
Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).
Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.
A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).
Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.
Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.
The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.
In one embodiment, the compositions of dsRNAs and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically, microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 271).
The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.
Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (M0310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (M0750), decaglycerol sequioleate (S0750), decaglycerol decaoleate (DA0750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.
Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or dsRNAs. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations featured in the invention will facilitate the increased systemic absorption of dsRNAs and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of dsRNAs and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.
Microemulsions may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the dsRNAs and nucleic acids featured in the invention. Penetration enhancers used in microemulsions may be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.
Liposomes
There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used herein, the term “liposome” means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.
Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo.
In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.
Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.
Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.
Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.
Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis
Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985).
Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).
One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.
Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., Journal of Drug Targeting, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., Antiviral Research, 1992, 18, 259-265).
Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems including non-ionic surfactant and cholesterol. Non-ionic liposomal formulations including NovasomeTM I (glyceryl dilaurate/cholesterol/po-lyoxyethylene-10-stearyl ether) and NovasomeTM II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. S. T. P. Pharma. Sci., 1994, 4, 6, 466).
Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes including one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) includes one or more glycolipids, such as monosialoganglioside GM1, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).
Various liposomes including one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside GM1, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes including (1) sphingomyelin and (2) the ganglioside GM1 or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes including sphingomyelin. Liposomes including 1,2-sn-dimyristoylphosphat-idylcholine are disclosed in WO 97/13499 (Lim et al).
Many liposomes including lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (Bull. Chem. Soc. Jpn., 1980, 53, 2778) described liposomes including a nonionic detergent, 2C1215G, that contains a PEG moiety. Ilium et al. (FEBS Lett., 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klibanov et al. (FEBS Lett., 1990, 268, 235) described experiments demonstrating that liposomes including phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (Biochimica et Biophysica Acta, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes including a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes including PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al). U.S. Pat. No. 5,540,935 (Miyazaki et al.) and U.S. Pat. No. 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.
A limited number of liposomes including nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an dsRNA RNA. U.S. Pat. No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes including dsRNA dsRNAs targeted to the raf gene.
Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.
Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the “head”) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.
If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.
If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.
If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.
The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
Penetration Enhancers
In one embodiment, various penetration enhancers are used to effect the efficient delivery of nucleic acids, particularly dsRNAs, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.
Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.
Surfactants (or “surface-active agents”) are chemical entities, which when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of dsRNAs through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).
Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C1-10 alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in Therapeutic Drug Carryier Systems, 1991, p. 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).
Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term “bile salts” includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).
“Chelating Agents” are defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of dsRNAs through the mucosa is enhanced. With regards to their use as penetration enhancers, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Chelating agents include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).
Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of dsRNAs through the alimentary mucosa (Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).
Agents that enhance uptake of dsRNAs at the cellular level may also be added to the pharmaceutical and other compositions featured in the invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of dsRNAs.
Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.
Carriers
Certain compositions featured herein also incorporate carrier compounds in the formulation. As used herein, “carrier compound” or “carrier” can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se), but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate dsRNA in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4′ isothiocyano-stilbene-2,2′-disulfonic acid (Miyao et al., DsRNA Res. Dev., 1995, 5, 115-121; Takakura et al., DsRNA & Nucl. Acid Drug Dev., 1996, 6, 177-183.
Excipients
In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc).
Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration, and that do not deleteriously react with nucleic acids, can also be used to formulate the compositions featured in the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.
Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.
Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.
Other Components
The compositions featured in the invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions featured in the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions featured in the invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.
Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.
Certain embodiments featured in the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other therapeutic agents which function by a non-antisense mechanism. For example, the one or more other therapeutic agents include antibiotic or antiviral agents. Exemplary antibiotics include, e.g., amphotericin B, norfloxacin, miconazole nitrate, ofloxacin, idoxuridine, chloramphenicol, colistin sodium methanesulfonate, carbenicillin sodium, beta-lactam antibiotics, cefoxitin, n-formanidolthienamycin and other thienamycin derivatives, tetracyclines, neomycin, carbenicillin, colistin, penicillin G, polymyxin B, vancomycin, cefazolin, cephaloridine, chibrorifamycin, gramicidin, bacitracin and sulfonamides. Exemplary antiviral agents include, e.g., acyclovir and interferon. For the treatment of autoimmune disease the one or more other therapeutic agents can include, e.g., interferon beta (e.g., IFNbeta-1a and IFN-1b, gliatriamer acetate (Copaxone), cyclophosphamide, methotrexate, azathioprine (Imuran), cladribine (Leustatin), cyclosporine, mitoxantrone, and glucocorticoids (e.g., adrenocorticotropic hormone (ACTH), methylprednisolone, and dexamethasone). For treatment of Graves' disease, for example, the additional therapeutic agent can be, e.g., an antithyroid drug, such as propylthiouracil (PTU) or methimazole. The invention also includes methods of treating a disorder described herein by administration of a dsRNA described herein and one or more other therapeutic agents which function by a non-antisense mechanism, e.g., one or more of the agents listed above. The agents can be administered in a single formulation or may be administered separately, at the same or at different times.
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Suitable compounds typically exhibit high therapeutic indices.
The data obtained from cell culture assays and animal studies can be used in formulation a range of dosage for use in humans. The dosage of compositions featured in the invention lies generally within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (e.g., achieving a decreased concentration of the polypeptide) that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
In addition to their administration individually or as a plurality, as discussed above, the dsRNAs featured in the invention can be administered in combination with other known agents effective in treatment of pathological processes mediated by CD45 expression. In any event, the administering physician can adjust the amount and timing of dsRNA administration on the basis of results observed using standard measures of efficacy known in the art or described herein.
Methods for Treating Diseases Caused by Expression of the CD45 Gene
In one embodiment, the invention provides a method for treating a subject having a pathological condition mediated by the expression of the CD45 gene, such as an autoimmune disease or an infectious disease. In this embodiment, the dsRNA acts as a therapeutic agent for controlling the expression of the CD45 protein. The method includes administering a pharmaceutical composition featured in the invention to the patient (e.g., human), such that expression of the CD45 gene is silenced. Because of their high specificity, the dsRNAs featured in the invention specifically target mRNAs of the CD45 gene.
As used herein, the term “CD45-mediated condition or disease” and related terms and phrases refer to a condition or disorder characterized by unwanted or inappropriate, e.g., abnormal CD45 activity. Inappropriate CD45 functional activity might arise as the result of CD45 expression in cells which normally do not express CD45, increased CD45 expression and/or activity (leading to, e.g., autoimmune disorders and diseases, or increased susceptibility to disease). A CD45-mediated condition or disease may be completely or partially mediated by inappropriate CD45 functional activity which may result by way of inappropriate activation of CD45. Regardless, a CD45-mediated condition or disease is one in which modulation of CD45 via RNA interference results in some effect on the underlying condition or disorder (e.g., a CD45 inhibitor results in some improvement in patient well-being in at least some patients).
The anti-CD45 dsRNAs featured in the present invention may be used to treat or diagnose an infection or immune disorder in a subject. The methods include administering to a subject an anti-CD45 dsRNA in an amount effective to treat an infectious disease or autoimmune disorder.
Pathological processes refer to a category of biological processes that produce a deleterious effect. For example, unregulated expression of CD45 is associated with autoimmunity and infectious disease. A compound featured in the invention can typically modulate a pathological process when the compound reduces the degree or severity of the process. For instance, autoimmunity or an infection may be prevented or related pathological processes can be modulated by the administration of compounds that reduce or modulate in some way the expression or at least one activity CD45.
The dsRNA molecules featured herein may, therefore, be used to treat an autoimmune or infectious disease. Autoimmune diseases that can be treated with a dsRNA that targets CD45 include, but are not limited to, Graves' disease, Hashimoto's thyroiditis, multiple sclerosis, and systemic sclerosis. In one embodiment, a dsRNA targeting CD45 is administered to a patient who has received an organ transplant, such as to reduce the risk of damage to the organ (e.g., from ischemia and reperfusion, such as caused by an inflammatory response) and the risk of organ rejection. Infectious diseases that can be treated with a dsRNA that targets CD45 include but are not limited to influenza, anthrax, Ebola, human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), rabies, Mokola, Rous sarcoma virus, and hepatitis, such as hepatitis A, B and C strains.
The pharmaceutical compositions encompassed by the invention may be administered by any means known in the art including, but not limited to oral or parenteral routes, including intravenous, intramuscular, intraarticular, intraperitoneal, subcutaneous, intravitreal, transdermal, airway (aerosol), nasal, rectal, vaginal and topical (including buccal and sublingual) administration, and epidural administration. In some embodiments, the pharmaceutical compositions are administered intraveneously by infusion or injection.
Before administration of a full dose of a dsRNA targeting CD45, a patient can be administered a smaller dose, such as a 5% infusion reaction, and monitored for adverse effects, such as an allergic reaction. In another example, the patient can be monitored for unwanted immunostimulatory effects, such as increased cytokine (e.g., TNF-alpha or INF-alpha) levels.
Many CD45-associated diseases and disorders are hereditary. Therefore, a patient in need of a dsRNA targeting CD45 can be identified by taking a family history. A healthcare provider, such as a doctor, nurse, or family member, can take a family history before prescribing or administering a dsRNA. A DNA test may also be performed on the patient to identify a mutation in the target gene, before a dsRNA is administered to the patient.
Methods for Inhibiting Expression of the CD45 Gene
In yet another aspect, the invention provides a method for inhibiting the expression of the CD45 gene in a mammal. The method includes administering a CD45 dsRNA to the mammal such that expression of the target CD45 gene is silenced. Because of their high specificity, the dsRNAs specifically target RNAs (primary or processed) of the target CD45 gene. Compositions and methods for inhibiting the expression of the CD45 gene using dsRNAs can be performed as described elsewhere herein.
In one embodiment, the method includes administering a composition including a dsRNA, wherein the dsRNA includes a nucleotide sequence which is complementary to at least a part of an RNA transcript of the CD45 gene of the mammal to be treated. When the organism to be treated is a mammal such as a human, the composition may be administered by any means known in the art including, but not limited to oral or parenteral routes, including intravenous, intramuscular, intraarticular, intracranial, subcutaneous, intravitreal, transdermal, airway (aerosol), nasal, rectal, vaginal and topical (including buccal and sublingual) administration. In some embodiments, the compositions are administered by intraveneous infusion or injection.







TABLE 1







Target positions of duplex dsRNAs













Human






Reference






NM_002838.2
SEQ
sequence of


Duplex
ID
pos. in
ID
total 23-mer


Name
#
23mer
NO:
target site





AD-14008
  69
2206-2228
 97
CAGAAUAAAAACCGUUAUGUUGA


 


AD-14009
 225
2213-2235
 98
AAAACCGUUAUGUUGACAUUCUU


 


AD-14010
 211
1927-1949
 99
UUUCUGAUUAUUGUGACAUCAAU


 


AD-14011
 224
2210-2232
100
AUAAAAACCGUUAUGUUGACAUU


 


AD-14012
 233
2326-2348
101
GAACCCAGGAAAUACAUUGCUGC


 


AD-14013
 222
2204-2226
102
ACCAGAAUAAAAACCGUUAUGUU


 


AD-14014
 223
2205-2227
103
CCAGAAUAAAAACCGUUAUGUUG


 


AD-14015
 235
2409-2431
104
CACAGUUAUUGUCAUGGUCACUC


 


AD-14016
 454
2207-2229
105
AGAAUAAAAACCGUUAUGUUGAC


 


AD-14017
 463
2329-2351
106
CCCAGGAAAUACAUUGCUGCACA


 


AD-14018
1389
2212-2234
107
AAAAACCGUUAUGUUGACAUUCU


 


AD-14019
 610
2211-2233
108
UAAAAACCGUUAUGUUGACAUUC


 


AD-14020
1094
2215-2237
109
AACCGUUAUGUUGACAUUCUUCC


 


AD-14021
 611
2214-2236
110
AAACCGUUAUGUUGACAUUCUUC


 


AD-14022
1388
2209-2231
111
AAUAAAAACCGUUAUGUUGACAU


 


AD-14023
1095
2216-2238
112
ACCGUUAUGUUGACAUUCUUCCU


 


AD-14024
1147
2408-2430
113
CCACAGUUAUUGUCAUGGUCACU


 


AD-14025
 725
1929-1951
114
UCUGAUUAUUGUGACAUCAAUAG


 


AD-14026
1364
1930-1952
115
CUGAUUAUUGUGACAUCAAUAGC


 


AD-14027
1124
2330-2352
116
CCAGGAAAUACAUUGCUGCACAA


 


AD-14028
1050
2028-2050
117
UGUUGAAAGGGAUGAUGAAAAAC


 


AD-14029
 609
2208-2230
118
GAAUAAAAACCGUUAUGUUGACA


 


AD-14030
 724
1928-1950
119
UUCUGAUUAUUGUGACAUCAAUA


 


AD-14031
1123
2327-2349
120
AACCCAGGAAAUACAUUGCUGCA


 


AD-14032
1125
2331-2353
121
CAGGAAAUACAUUGCUGCACAAG


 


AD-14033
1146
2407-2429
122
GCCACAGUUAUUGUCAUGGUCAC


 


AD-14034
1403
2436-2458
123
UGAAGAAGGAAACAGGAACAAGU


 


AD-14035
1365
1931-1953
124
UGAUUAUUGUGACAUCAAUAGCC


 


AD-14036
1394
2328-2350
125
ACCCAGGAAAUACAUUGCUGCAC


 


AD-14037
1154
2431-2453
126
CGAUGUGAAGAAGGAAACAGGAA


 


AD-14038
1022
1932-1954
127
GAUUAUUGUGACAUCAAUAGCCC


 


AD-14039
1121
2324-2346
128
AAGAACCCAGGAAAUACAUUGCU


 


AD-14040
1122
2325-2347
129
AGAACCCAGGAAAUACAUUGCUG


 


AD-14041
 760
2405-2427
130
AAGCCACAGUUAUUGUCAUGGUC


 


AD-14042
1401
2429-2451
131
CUCGAUGUGAAGAAGGAAACAGG


 


AD-14043
1153
2430-2452
132
UCGAUGUGAAGAAGGAAACAGGA


 


AD-14044
1402
2432-2454
133
GAUGUGAAGAAGGAAACAGGAAC


 


AD-14045
1155
2433-2455
134
AUGUGAAGAAGGAAACAGGAACA


 


AD-14046
 744
2217-2239
135
CCGUUAUGUUGACAUUCUUCCUU


 


AD-14047
1701
2406-2428
136
AGCCACAGUUAUUGUCAUGGUCA


 


AD-14048
1704
2439-2461
137
AGAAGGAAACAGGAACAAGUGUG


 


AD-14049
1833
2435-2457
138
GUGAAGAAGGAAACAGGAACAAG


 


AD-14050
1564
2133-2155
139
UCUGGCUGAAUUUCAGAGCAUCC


 


AD-14051
1657
2027-2049
140
UUGUUGAAAGGGAUGAUGAAAAA


 


AD-14052
1673
2132-2154
141
UUCUGGCUGAAUUUCAGAGCAUC


 


AD-14053
1648
1926-1948
142
AUUUCUGAUUAUUGUGACAUCAA


 


AD-14054
1703
2437-2459
143
GAAGAAGGAAACAGGAACAAGUG


 


AD-14055
1647
1925-1947
144
CAUUUCUGAUUAUUGUGACAUCA
















TABLE 2







Sense and Antisense sequences of duplex dsRNAs



















Antisense strand





Sense strand sequence


sequence



SEQ

(5′ to 3′)
SEQ

(5′ to 3′)


Duplex
ID

Double overhang
ID

Double overhang


Name
NO:
Name
design
NO:
Name
design





AD-14008
 1
A22737
GAAuAAAAAccGuuAuGuuTsT
 2
A22738
AAcAuAACGGUUUUuAUUCTsT


 


AD-14009
 3
A22739
AAccGuuAuGuuGAcAuucTsT
 4
A22740
GAAUGUcAAcAuAACGGUUTsT


 


AD-14010
 5
A22741
ucuGAuuAuuGuGAcAucATsT
 6
A22742
UGAUGUcAcAAuAAUcAGATsT


 


AD-14011
 7
A22743
AAAAAccGuuAuGuuGAcATsT
 8
A22744
UGUcAAcAuAACGGUUUUUTsT


 


AD-14012
 9
A22745
AcccAGGAAAuAcAuuGcuTsT
10
A22746
AGcAAUGuAUUUCCUGGGUTsT


 


AD-14013
11
A22747
cAGAAuAAAAAccGuuAuGTsT
12
A22748
cAuAACGGUUUUuAUUCUGTsT


 


AD-14014
13
A22749
AGAAuAAAAAccGuuAuGuTsT
14
A22750
AcAuAACGGUUUUuAUUCUTsT


 


AD-14015
15
A22751
cAGuuAuuGucAuGGucAcTsT
16
A22752
GUGACcAUGAcAAuAACUGTsT


 


AD-14016
17
A22753
AAuAAAAAccGuuAuGuuGTsT
18
A22754
cAAcAuAACGGUUUUuAUUTsT


 


AD-14017
19
A22755
cAGGAAAuAcAuuGcuGcATsT
20
A22756
UGcAGcAAUGuAUUUCCUGTsT


 


AD-14018
21
A22757
AAAccGuuAuGuuGAcAuuTsT
22
A22758
AAUGUcAAcAuAACGGUUUTsT


 


AD-14019
23
A22759
AAAAccGuuAuGuuGAcAuTsT
24
A22760
AUGUcAAcAuAACGGUUUUTsT


 


AD-14020
25
A22761
ccGuuAuGuuGAcAuucuuTsT
26
A22762
AAGAAUGUcAAcAuAACGGTsT


 


AD-14021
27
A22763
AccGuuAuGuuGAcAuucuTsT
28
A22764
AGAAUGUcAAcAuAACGGUTsT


 


AD-14022
29
A22765
uAAAAAccGuuAuGuuGAcTsT
30
A22766
GUcAAcAuAACGGUUUUuATsT


 


AD-14023
31
A22767
cGuuAuGuuGAcAuucuucTsT
32
A22768
GAAGAAUGUcAAcAuAACGTsT


 


AD-14024
33
A22769
AcAGuuAuuGucAuGGucATsT
34
A22770
UGACcAUGAcAAuAACUGUTsT


 


AD-14025
35
A22771
uGAuuAuuGuGAcAucAAuTsT
36
A22772
AUUGAUGUcAcAAuAAUcATsT


 


AD-14026
37
A22773
GAuuAuuGuGAcAucAAuATsT
38
A22774
uAUUGAUGUcAcAAuAAUCTsT


 


AD-14027
39
A22775
AGGAAAuAcAuuGcuGcAcTsT
40
A22776
GUGcAGcAAUGuAUUUCCUTsT


 


AD-14028
41
A22777
uuGAAAGGGAuGAuGAAAATsT
42
A22778
UUUUcAUcAUCCCUUUcAATsT


 


AD-14029
43
A22779
AuAAAAAccGuuAuGuuGATsT
44
A22780
UcAAcAuAACGGUUUUuAUTsT


 


AD-14030
45
A22781
cuGAuuAuuGuGAcAucAATsT
46
A22782
UUGAUGUcAcAAuAAUcAGTsT


 


AD-14031
47
A22783
cccAGGAAAuAcAuuGcuGTsT
48
A22784
cAGcAAUGuAUUUCCUGGGTsT


 


AD-14032
49
A22785
GGAAAuAcAuuGcuGcAcATsT
50
A22786
UGUGcAGcAAUGuAUUUCCTsT


 


AD-14033
51
A22787
cAcAGuuAuuGucAuGGucTsT
52
A22788
GACcAUGAcAAuAACUGUGTsT


 


AD-14034
53
A22789
AAGAAGGAAAcAGGAAcAATsT
54
A22790
UuGUUCCuGUUUCCUUCUUTsT


 


AD-14035
55
A22791
AuuAuuGuGAcAucAAuAGTsT
56
A22792
CuAUUGAUGUcAcAAuAAUTsT


 


AD-14036
57
A22793
ccAGGAAAuAcAuuGcuGcTsT
58
A22794
GcAGcAAUGuAUUUCCUGGTsT


 


AD-14037
59
A22795
AuGuGAAGAAGGAAAcAGGTsT
60
A22796
CCUGUUUCCUUCUUcAcAUTsT


 


AD-14038
61
A22797
uuAuuGuGAcAucAAuAGcTsT
62
A22798
GCuAUUGAUGUcAcAAuAATsT


 


AD-14039
63
A22799
GAAcccAGGAAAuAcAuuGTsT
64
A22800
cAAUGuAUUUCCUGGGUUCTsT


 


AD-14040
65
A22801
AAcccAGGAAAuAcAuuGcTsT
66
A22802
GcAAUGuAUUUCCUGGGUUTsT


 


AD-14041
67
A22803
GccAcAGuuAuuGucAuGGTsT
68
A22804
CcAUGAcAAuAACUGUGGCTsT


 


AD-14042
69
A22805
cGAuGuGAAGAAGGAAAcATsT
70
A22806
UGUUUCCUUCUUcAcAUCGTsT


 


AD-14043
71
A22807
GAuGuGAAGAAGGAAAcAGTsT
72
A22808
CUGUUUCCUUCUUcAcAUCTsT


 


AD-14044
73
A22809
uGuGAAGAAGGAAAcAGGATsT
74
A22810
UCCUGUUUCCUUCUUcAcATsT


 


AD-14045
75
A22811
GuGAAGAAGGAAAcAGGAATsT
76
A22812
UUCCUGUUUCCUUCUUcACTsT


 


AD-14046
77
A22813
GuuAuGuuGAcAuucuuccTsT
78
A22814
GGAAGAAUGUcAAcAuAACTsT


 


AD-14047
79
A22815
ccAcAGuuAuuGucAuGGuTsT
80
A22816
ACcAUGAcAAuAACUGUGGTsT


 


AD-14048
81
A22817
AAGGAAAcAGGAAcAAGuGTsT
82
A22818
cACUUGUUCCUGUUUCCUUTsT


 


AD-14049
83
A22819
GAAGAAGGAAAcAGGAAcATsT
84
A22820
uGUUCCuGUUUCCUUCUUCTsT


 


AD-14050
85
A22821
uGGcuGAAuuucAGAGcAuTsT
86
A22822
AUGCUCUGAAAUUcAGCcATsT


 


AD-14051
87
A22823
GuuGAAAGGGAuGAuGAAATsT
88
A22824
UUUcAUcAUCCCUUUcAACTsT


 


AD-14052
89
A22825
cuGGcuGAAuuucAGAGcATsT
90
A22826
UGCUCUGAAAUUcAGCcAGTsT


 


AD-14053
91
A22827
uucuGAuuAuuGuGAcAucTsT
92
A22828
GAUGUcAcAAuAAUcAGAATsT


 


AD-14054
93
A22829
AGAAGGAAAcAGGAAcAAGTsT
94
A22830
CUuGUUCCuGUUUCCUUCUTsT


 


AD-14055
95
A22831
uuucuGAuuAuuGuGAcAuTsT
96
A22832
AUGUcAcAAuAAUcAGAAATsT
















TABLE 3







Efficacy of duplex dsRNAs















Duplex
Percent

IC20 (nM)
IC50 (nM)
IC80 (nM)
IC20 (nM)
IC50 (nM)
IC80 (nM)


Name
Inhibitiona
SDb
(FACS)
(FACS)
(FACS)
(bDNA)
(bDNA)
(bDNA)


















AD-14008
86%
1%
0.8895931
#N/A
#N/A
0.03996853
0.2361971
#N/A


AD-14009
34%
2%


AD-14010
38%
3%


AD-14011
11%
4%


AD-14012
62%
5%


AD-14013
60%
1%


AD-14014
10%
8%


AD-14015
71%
3%


AD-14016
16%
10%


AD-14017
46%
6%


AD-14018
84%
0%



0.01773181
0.12385771
#N/A


AD-14019
50%
6%


AD-14020
75%
3%


AD-14021
83%
5%
0.05351334
0.28749645
#N/A
0.00767305
0.06871733
3.50954466


AD-14022
18%
9%


AD-14023
82%
3%
0.16806395
1.15022087
#N/A
0.01854289
0.18153564
42.4598925


AD-14024
45%
8%


AD-14025
72%
3%


AD-14026
68%
4%


AD-14027
20%
2%


AD-14028
79%
3%



0.04248737
0.28602921
#N/A


AD-14029
54%
1%


AD-14030
74%
3%


AD-14031
79%
4%



0.6082823
1.9630781
#N/A


AD-14032
61%
10%


AD-14033
23%
6%


AD-14034
55%
4%


AD-14035
25%
0%


AD-14036
63%
2%


AD-14037
78%
7%


AD-14038
12%
1%


AD-14039
33%
5%


AD-14040
17%
3%


AD-14041
32%
0%


AD-14042
78%
4%



0.00990567
0.08334966
#N/A


AD-14043
44%
5%


AD-14044
59%
6%


AD-14045
58%
4%


AD-14046
50%
5%


AD-14047
65%
2%


AD-14048
12%
4%


AD-14049
72%
2%


AD-14050
52%
9%


AD-14051
64%
3%


AD-14052
89%
4%
0.06652968
0.30445773
#N/A
0.00543153
0.04500437
1.02650598


AD-14053
78%
3%



0.01679891
0.14666108
#N/A


AD-14054
70%
8%


AD-14055
26%
3%





aPercent inhibition of CD45 expression (relative to irrelevant control siRNA-treated cells; mean of three screens); by bDNA assay, 50 nM in P388D1.


bStandard Deviation (mean of three screens)













TABLE 4







Exemplary unmodified dsRNAs targeting CD45.















Antisense strand


position of

Sense strand sequence

sequence


5′ base on
SEQ
(5′ to 3′)
SEQ
(5′ to 3′)


transcript
ID
Double overhang
ID
Double overhang


NM_002838.2
NO:
Design
NO:
design





2208
147
GAAUAAAAACCGUUAUGUU
148
AACAUAACGGUUUUUAUUC


 


2215
149
AACCGUUAUGUUGACAUUC
150
GAAUGUCAACAUAACGGUU


 


1929
151
UCUGAUUAUUGUGACAUCA
152
UGAUGUCACAAUAAUCAGA


 


2212
153
AAAAACCGUUAUGUUGACA
154
UGUCAACAUAACGGUUUUU


 


2328
155
ACCCAGGAAAUACAUUGCU
156
AGCAAUGUAUUUCCUGGGU


 


2206
157
CAGAAUAAAAACCGUUAUG
158
CAUAACGGUUUUUAUUCUG


 


2207
159
AGAAUAAAAACCGUUAUGU
160
ACAUAACGGUUUUUAUUCU


 


2411
161
CAGUUAUUGUCAUGGUCAC
162
GUGACCAUGACAAUAACUG


 


2209
163
AAUAAAAACCGUUAUGUUG
164
CAACAUAACGGUUUUUAUU


 


2331
165
CAGGAAAUACAUUGCUGCA
166
UGCAGCAAUGUAUUUCCUG


 


2214
167
AAACCGUUAUGUUGACAUU
168
AAUGUCAACAUAACGGUUU


 


2213
169
AAAACCGUUAUGUUGACAU
170
AUGUCAACAUAACGGUUUU


 


2217
171
CCGUUAUGUUGACAUUCUU
172
AAGAAUGUCAACAUAACGG


 


2216
173
ACCGUUAUGUUGACAUUCU
174
AGAAUGUCAACAUAACGGU


 


2211
175
UAAAAACCGUUAUGUUGAC
176
GUCAACAUAACGGUUUUUA


 


2218
177
CGUUAUGUUGACAUUCUUC
178
GAAGAAUGUCAACAUAACG


 


2410
179
ACAGUUAUUGUCAUGGUCA
180
UGACCAUGACAAUAACUGU


 


1931
181
UGAUUAUUGUGACAUCAAU
182
AUUGAUGUCACAAUAAUCA


 


1932
183
GAUUAUUGUGACAUCAAUA
184
UAUUGAUGUCACAAUAAUC


 


2332
185
AGGAAAUACAUUGCUGCAC
186
GUGCAGCAAUGUAUUUCCU


 


2030
187
UUGAAAGGGAUGAUGAAAA
188
UUUUCAUCAUCCCUUUCAA


 


2210
189
AUAAAAACCGUUAUGUUGA
190
UCAACAUAACGGUUUUUAU


 


1930
191
CUGAUUAUUGUGACAUCAA
192
UUGAUGUCACAAUAAUCAG


 


2329
193
CCCAGGAAAUACAUUGCUG
194
CAGCAAUGUAUUUCCUGGG


 


2333
195
GGAAAUACAUUGCUGCACA
196
UGUGCAGCAAUGUAUUUCC


 


2409
197
CACAGUUAUUGUCAUGGUC
198
GACCAUGACAAUAACUGUG


 


2438
199
AAGAAGGAAACAGGAACAA
200
UUGUUCCUGUUUCCUUCUU


 


1933
201
AUUAUUGUGACAUCAAUAG
202
CUAUUGAUGUCACAAUAAU


 


2330
203
CCAGGAAAUACAUUGCUGC
204
GCAGCAAUGUAUUUCCUGG


 


2433
205
AUGUGAAGAAGGAAACAGG
206
CCUGUUUCCUUCUUCACAU


 


1934
207
UUAUUGUGACAUCAAUAGC
208
GCUAUUGAUGUCACAAUAA


 


2326
209
GAACCCAGGAAAUACAUUG
210
CAAUGUAUUUCCUGGGUUC


 


2327
211
AACCCAGGAAAUACAUUGC
212
GCAAUGUAUUUCCUGGGUU


 


2407
213
GCCACAGUUAUUGUCAUGG
214
CCAUGACAAUAACUGUGGC


 


2431
215
CGAUGUGAAGAAGGAAACA
216
UGUUUCCUUCUUCACAUCG


 


2432
217
GAUGUGAAGAAGGAAACAG
218
CUGUUUCCUUCUUCACAUC


 


2434
219
UGUGAAGAAGGAAACAGGA
220
UCCUGUUUCCUUCUUCACA


 


2435
221
GUGAAGAAGGAAACAGGAA
222
UUCCUGUUUCCUUCUUCAC


 


2219
223
GUUAUGUUGACAUUCUUCC
224
GGAAGAAUGUCAACAUAAC


 


2408
225
CCACAGUUAUUGUCAUGGU
226
ACCAUGACAAUAACUGUGG


 


2441
227
AAGGAAACAGGAACAAGUG
228
CACUUGUUCCUGUUUCCUU


 


2437
229
GAAGAAGGAAACAGGAACA
230
UGUUCCUGUUUCCUUCUUC


 


2135
231
UGGCUGAAUUUCAGAGCAU
232
AUGCUCUGAAAUUCAGCCA


 


2029
233
GUUGAAAGGGAUGAUGAAA
234
UUUCAUCAUCCCUUUCAAC


 


2134
235
CUGGCUGAAUUUCAGAGCA
236
UGCUCUGAAAUUCAGCCAG


 


1928
237
UUCUGAUUAUUGUGACAUC
238
GAUGUCACAAUAAUCAGAA


 


2439
239
AGAAGGAAACAGGAACAAG
240
CUUGUUCCUGUUUCCUUCU


 


1927
241
UUUCUGAUUAUUGUGACAU
242
AUGUCACAAUAAUCAGAAA
















TABLE 4







Exemplary dsRNAs having NN-dinucleotide overhangs and


targeting CD45.













Sense strand

Antisense strand


position of

 sequence

sequence


5′ base on
SEQ
(5′ to 3′)
SEQ
(5′ to 3′)


transcript
ID
Double overhang
ID
Double overhang


NM_002838.2
NO:
Design
NO:
design





2208
243
GAAUAAAAACCGUUAUGUUNN
244
AACAUAACGGUUUUUAUUCNN


 


2215
245
AACCGUUAUGUUGACAUUCNN
246
GAAUGUCAACAUAACGGUUNN


 


1929
247
UCUGAUUAUUGUGACAUCANN
248
UGAUGUCACAAUAAUCAGANN


 


2212
249
AAAAACCGUUAUGUUGACANN
250
UGUCAACAUAACGGUUUUUNN


 


2328
251
ACCCAGGAAAUACAUUGCUNN
252
AGCAAUGUAUUUCCUGGGUNN


 


2206
253
CAGAAUAAAAACCGUUAUGNN
254
CAUAACGGUUUUUAUUCUGNN


 


2207
255
AGAAUAAAAACCGUUAUGUNN
256
ACAUAACGGUUUUUAUUCUNN


 


2411
257
CAGUUAUUGUCAUGGUCACNN
258
GUGACCAUGACAAUAACUGNN


 


2209
259
AAUAAAAACCGUUAUGUUGNN
260
CAACAUAACGGUUUUUAUUNN


 


2331
261
CAGGAAAUACAUUGCUGCANN
262
UGCAGCAAUGUAUUUCCUGNN


 


2214
263
AAACCGUUAUGUUGACAUUNN
264
AAUGUCAACAUAACGGUUUNN


 


2213
265
AAAACCGUUAUGUUGACAUNN
266
AUGUCAACAUAACGGUUUUNN


 


2217
267
CCGUUAUGUUGACAUUCUUNN
268
AAGAAUGUCAACAUAACGGNN


 


2216
269
ACCGUUAUGUUGACAUUCUNN
270
AGAAUGUCAACAUAACGGUNN


 


2211
271
UAAAAACCGUUAUGUUGACNN
272
GUCAACAUAACGGUUUUUANN


 


2218
273
CGUUAUGUUGACAUUCUUCNN
274
GAAGAAUGUCAACAUAACGNN


 


2410
275
ACAGUUAUUGUCAUGGUCANN
276
UGACCAUGACAAUAACUGUNN


 


1931
277
UGAUUAUUGUGACAUCAAUNN
278
AUUGAUGUCACAAUAAUCANN


 


1932
279
GAUUAUUGUGACAUCAAUANN
280
UAUUGAUGUCACAAUAAUCNN


 


2332
281
AGGAAAUACAUUGCUGCACNN
282
GUGCAGCAAUGUAUUUCCUNN


 


2030
283
UUGAAAGGGAUGAUGAAAANN
284
UUUUCAUCAUCCCUUUCAANN


 


2210
285
AUAAAAACCGUUAUGUUGANN
286
UCAACAUAACGGUUUUUAUNN


 


1930
287
CUGAUUAUUGUGACAUCAANN
288
UUGAUGUCACAAUAAUCAGNN


 


2329
289
CCCAGGAAAUACAUUGCUGNN
290
CAGCAAUGUAUUUCCUGGGNN


 


2333
291
GGAAAUACAUUGCUGCACANN
292
UGUGCAGCAAUGUAUUUCCNN


 


2409
293
CACAGUUAUUGUCAUGGUCNN
294
GACCAUGACAAUAACUGUGNN


 


2438
295
AAGAAGGAAACAGGAACAANN
296
UUGUUCCUGUUUCCUUCUUNN


 


1933
297
AUUAUUGUGACAUCAAUAGNN
298
CUAUUGAUGUCACAAUAAUNN


 


2330
299
CCAGGAAAUACAUUGCUGCNN
300
GCAGCAAUGUAUUUCCUGGNN


 


2433
301
AUGUGAAGAAGGAAACAGGNN
302
CCUGUUUCCUUCUUCACAUNN


 


1934
303
UUAUUGUGACAUCAAUAGCNN
304
GCUAUUGAUGUCACAAUAANN


 


2326
305
GAACCCAGGAAAUACAUUGNN
306
CAAUGUAUUUCCUGGGUUCNN


 


2327
307
AACCCAGGAAAUACAUUGCNN
308
GCAAUGUAUUUCCUGGGUUNN


 


2407
309
GCCACAGUUAUUGUCAUGGNN
310
CCAUGACAAUAACUGUGGCNN


 


2431
311
CGAUGUGAAGAAGGAAACANN
312
UGUUUCCUUCUUCACAUCGNN


 


2432
313
GAUGUGAAGAAGGAAACAGNN
314
CUGUUUCCUUCUUCACAUCNN


 


2434
315
UGUGAAGAAGGAAACAGGANN
316
UCCUGUUUCCUUCUUCACANN


 


2435
317
GUGAAGAAGGAAACAGGAANN
318
UUCCUGUUUCCUUCUUCACNN


 


2219
319
GUUAUGUUGACAUUCUUCCNN
320
GGAAGAAUGUCAACAUAACNN


 


2408
321
CCACAGUUAUUGUCAUGGUNN
322
ACCAUGACAAUAACUGUGGNN


 


2441
323
AAGGAAACAGGAACAAGUGNN
324
CACUUGUUCCUGUUUCCUUNN


 


2437
325
GAAGAAGGAAACAGGAACANN
326
UGUUCCUGUUUCCUUCUUCNN


 


2135
327
UGGCUGAAUUUCAGAGCAUNN
328
AUGCUCUGAAAUUCAGCCANN


 


2029
329
GUUGAAAGGGAUGAUGAAANN
330
UUUCAUCAUCCCUUUCAACNN


 


2134
331
CUGGCUGAAUUUCAGAGCANN
332
UGCUCUGAAAUUCAGCCAGNN


 


1928
333
UUCUGAUUAUUGUGACAUCNN
334
GAUGUCACAAUAAUCAGAANN


 


2439
335
AGAAGGAAACAGGAACAAGNN
336
CUUGUUCCUGUUUCCUUCUNN


 


1927
337
UUUCUGAUUAUUGUGACAUNN
338
AUGUCACAAUAAUCAGAAANN









Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
EXAMPLES
Example 1
In Silico Selection of siRNAs Targeting CD45
siRNA design was carried out to identify siRNAs targeting CD45 (also known PTPRC, B220, CD45, GP180, LCA, LY5, and T200). Human mRNA sequences to CD45, RefSeq ID number: NM—002838.3, NM—080921.2, NM—080922.2, NM—080923.2, Y00062.1, Y00638.1, BC014239.2, BC017863.1, BC031525.1, BC121086.1, BC121087.1, BC127656.1, BC127657.1, AY429565.1, AY567999.1, AK130573.1, DA670254.1, DA948670.1, AY429566.1, and CR621867.1 were used. Mouse mRNA sequences to CD45, RefSeq ID number: NM—011210.2, AK054056.1, AK088215.1, AK154893.1, AK171802.1, BC028512.1, EF101553.1, L36091.1, M11934.1, M14342.1, M14343.1, M15174.1, M17320.1, and M92933.1 were used. Rhesus monkey mRNA sequence to CD45, RefSeqID number; XR—012672.1 was also used.
siRNA duplexes cross-reactive to human, mouse and rhesus CD45 transcripts were designed. Forty-eight duplexes were synthesized and screened as outlined in Tables 1-3.
The sequences for human, mouse and partial rhesus CD45 mRNAs were downloaded from NCBI Nucleotide database and the human sequence (Human CD45: NM—002838.3, 5330 bp) was further used as reference sequence.
For identification of further rhesus CD45 sequences, a blast search with the human reference sequence was conducted at NCBI against the rhesus reference genome. The downloaded rhesus sequence and the hit regions in the blast hit were assembled to a rhesus consensus sequence with 91% identity to human CD45 reference sequence over the full-length.
All conserved 19 mers were extracted from the human mRNA reference sequence, resulting in the pool of candidate target sites corresponding to 5312 (sense strand) sequences. Human-mouse-rhesus cross-reactivity was defined as a prerequisite for in silico selection of siRNAs out of this candidate pool. As no conserved regions are present in all human and/or mouse variants, the criterion for selection was relaxed to cross-reactivity to most relevant human and mouse CD45 sequences, which we assumed to be RefSeq sequences as well as other mRNAs for which protein expression has been described.
To determine cross-reactivity to human and mouse CD45 variants and rhesus-reactive siRNAs, the presence of each candidate siRNA target site was searched in the sequences.
Further, the predicted specificity of the siRNA was used as criterion for selection out of the pool of human-mouse-rhesus cross-reactive siRNAs, manifested by targeting human CD45 mRNA sequences, but not other human mRNAs.
The specificity of an siRNA can be expressed via its potential to target other genes, which are referred to as “off-target genes.” For predicting the off-target potential of an siRNA, the following assumptions were made: (1) off-target potential of a strand can be deduced from the number and distribution of mismatches to an off-target; (2) the most relevant off-target, that is the gene predicted to have the highest probability to be silenced due to tolerance of mismatches, determines the off-target potential of the strand; (3) positions 2 to 9 (counting 5′ to 3′) of a strand (seed region) may contribute more to off-target potential than the rest of the sequence (that is non-seed and cleavage site region); (4) positions 10 and 11 (counting 5′ to 3′) of a strand (cleavage site region) may contribute more to off-target potential than non-seed region (that is positions 12 to 18, counting 5′ to 3′); (5) positions 1 and 19 of each strand are not relevant for off-target interactions; (6) off-target potential can be expressed by the off-target score of the most relevant off-target, calculated based on number and position of mismatches of the strand to the most homologous region in the off-target gene considering assumptions 3 to 5; and (7) off-target potential of antisense and sense strand will be relevant, whereas potential abortion of sense strand activity by internal modifications introduced is likely.
SiRNAs with low off-target potential were defined as preferable and assumed to be more specific.
In order to identify human CD45-specific siRNAs, all other human transcripts that were considered potential off-targets, were searched for potential target regions for human-mouse-rhesus cross-reactive 19 mer sense strand sequences as well as complementary antisense strands. For this, the fastA algorithm was used to determine the most homologous hit region in each sequence of the human RefSeq database, which we assume to represent the comprehensive human transcriptome.
FastA output files were analyzed further by a Perl script to rank all potential off-targets according to assumptions 3′ to 5′, and thus to identify the most relevant off-target gene and its off-target score.
The script extracted the following off-target properties for each 19 mer input sequence and each off-target gene to calculate the off-target score:
Number of mismatches in non-seed region, number of mismatches in seed region, and number of mismatches in cleavage site region.
The off-target score was calculated by considering assumptions 3 to 5 as follows:

Off-target score=number of seed mismatches*10

+number of cleavage site mismatches*1.2

+number of non-seed mismatches*1

The most relevant off-target gene for each 19 mer sequence was defined as the gene with the lowest off-target score. Accordingly, the lowest off-target score was defined as representative for the off-target potential of a strand.
For the siRNA set in Table 2, cross-reactivity to rhesus, all human and mouse RefSeq sequences as well as to most variants with described protein was defined as prerequisite for selection. Further criterion was an off-target score of 1 or more for the antisense strand, whereas all sequences containing 4 or more consecutive G's (poly-G sequences) were excluded. 48 human-mouse-rhesus cross-reactive sequences that do not possess most-relevant off-targets predicted to be expressed in immune cells were selected (Tables 1 and 2).
Table 1 shows CD45 target sequences, Table 2 shows CD45 siRNAs, and Table 3 shows the IC values for the siRNAs tested in a dose response assay. Table 4 shows exemplary CD45 siRNAs that are not modified, and Table 5 shows exemplary CD45 siRNAs having dinucleotide overhangs.
Nucleic acid sequences are represented below using standard nomenclature, and specifically the abbreviations of Table 6.







TABLE 6







Abbreviations of nucleotide monomers used in nucleic acid sequence


representation. It will be understood that these monomers, when present


in an oligonucleotide, are mutually linked by 5′-3′-phosphodiester bonds.










Abbreviationa
Nucleotide(s)







A
Adenosine



C
cytidine



G
guanosine



T
thymidine



U
uridine



N
any nucleotide (G, A, C, U, T)



a
2′-O-methyladenosine



c
2′-O-methylcytidine



g
2′-O-methylguanosine



u
2′-O-methyluridine



dT
2′-deoxythymidine



s
a phosphorothioate linkage










Example 2
Screening Assay
48 human-mouse-rhesus cross-reactive siRNAs were first screened at 50 nM single dose (three independent screens, each done in quadruplicate) by bDNA assay in P388D1 cells. For the most potent siRNAs, dose response was performed by bDNA analysis in P388D1 to identify the IC20, IC50 and IC80 dose that lowers the level of CD45 transcript by 20, 50 and 80%, respectively. siRNAs with the best IC values in the bDNA assay were screened by flow cytometry to identify the IC20, IC50 and IC80 dose required to lower the amount of CD45 protein by 20, 50 and 80%, respectively.
Cell Line.
A P388D1 mouse macrophage cell line was obtained from the American Type Culture Collection (ATCC, Rockville Md., USA; ATCC # TIB-63) and grown in DMEM containing 10% heat-inactivated fetal bovine serum (FBS), 4 mM L-glutamine, 1.5 g/L sodium bicarbonate at 37° C. under a 5% CO2/95% air atmosphere at 37° C.
Cell Culture, siRNA Transfection.
P388D1 cells were plated in 24-well plates at 8×104 cells per well in 0.4 ml growth medium a day before transfection. P388D1 cells were 80% confluent the day of siRNA transfection. Before transfection, cells are fed with 0.25 ml growth medium.
Prior to adding to cells, 1.5 ml (50 μl per well) Optimem I (Invitrogen) and 90 μl (3 μl per well) Lipofectamin 2000 (Invitrogen), the amount sufficient for transfection of one 24 well plate, were combined in a 2 ml Sarstedt tube and incubated for 10-15 minutes at room temperature. The appropriate amount of siRNA dissolved in transfection buffer is then added to the Optimem/lipofectamine 2000 mixture to give the desired final concentration, mixed, and incubated an additional 15-25 minutes at room temperature. 50 μl of the siRNA/reagent complex was then added dropwise to each well as dictated by the experimental design. Plates were then gently rocked to ensure complete mixing and incubated at 37° C. at 5% CO2/95% air for 48 hours. The cells were lysed and CD45 mRNA transcript was quantitated in relation to a house-keeping gene transcript by branched DNA (bDNA) assay. CD45 protein expression level was determined by flow cytometry, for this assay cells were harvested by pipetting without lysing.
siRNA to CD45 Silenced CD45 in Mouse Macrophages In Vivo.
C57B1/6J mice (Jackson Labs) were injected intraperitoneally with 1 mL of 4% Brewers thioglycollate medium (Difco) 3 days prior to injecting 10 mg/kg of 98N12-5 formulated siCD45 or siGFP i.p. (4 mice per group). The thioglycollate acted as a sterile inflammation stimulus. Peritoneal lavage was collected 4 days later and stained with fluorophore conjugated antibodies to CD11b, Gr1 and CD45 (BD Biosciences). Flow cytometry samples were run on the LSR11 flow cytometer (BD Biosciences) and FlowJo software (Treestar) was used to identify the CD 11bhigh Gr1low macrophage population and quantify CD45 expression. A 65% reduction of CD45 protein expression was observed in the peritoneal macrophage population when treated with the formulated CD45 siRNA (FIG. 1). Two independent dose response experiments were conducted examining the effect of 0.6-15.0 mg/kg administration of 98N12-5 formulated siCD45 or siGFP i.p. (2-3 mice per group). These experiments were conducted identically to those described above and demonstrated effective specific in vivo silencing of CD45 protein expression at all concentrations tested when treated with the formulated CD45 siRNA (FIG. 1, top panel). The 98N12-5 formulation is a lipidoid synthesized by addition of acrylamides or acrylates to amines.
The sequences for the sense and antisense strands of the CD45 siRNA are as follows.









(SEQ ID NO: 89 single strand # A22825)



5′-cuGGcuGAAuuucAGAGcATsT-3′ sense



 



(SEQ ID NO: 90 single strand #_A22826)



5′-UGCUCUGAAAUUcAGCcAGTsT-3′ antisense






The siGFP sequences are as follows:









(SEQ ID NO: 145) (single strand # AL4545)



5′-CcAcAuGAAGcAGcACGACusU-3′ sense



 



(SEQ ID NO: 146) (single strand # AL4381)



5′-AAGUCGUGCUGCUUCAUGUGgsusC-3′ antisense






2′-O-Me modified nucleotides are in lower case, and phosphorothioate linkages are represented by an “s”. siRNAs were generated by annealing equimolar amounts of complementary sense and antisense strands.
All procedures used in animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) and were consistent with local, state, and federal regulations as applicable.
Lipidoid-based siRNA formulations included lipidoid, cholesterol, poly(ethylene glycol)-lipid (PEG-lipid), and siRNA. Formulations were prepared using a protocol similar to that described by Semple and colleagues (Maurer et al. Biophys. J. 80:2310-2326, 2001; Semple et al., Biochim. Biophys. Acta 1510:152-166, 2001). Stock solutions of 98N12-5(1).4HClMW 1489, mPEG2000-Ceramide C16 (Avanti Polar Lipids) MW 2634 or mPEG2000-DMG MW 2660, and cholesterol MW 387 (Sigma-Aldrich) were prepared in ethanol and mixed to yield a molar ratio of 42:10:48. Mixed lipids were added to 125 mM sodium acetate buffer pH 5.2 to yield a solution containing 35% ethanol, resulting in spontaneous formation of empty lipidoid nanoparticles. Resulting nanoparticles were extruded through a 0.08μ membrane (2 passes). siRNA in 35% ethanol and 50 mM sodium acetate pH 5.2 was added to the nanoparticles at 1:7.5 (wt:wt) siRNA:total lipids and incubated at 37° C. for 30 min. Ethanol removal and buffer exchange of siRNA-containing lipidoid nanoparticles was achieved by tangential flow filtration against phosphate buffered saline using a 100,000 MWCO membrane. Finally, the formulation was filtered through a 0.2μ sterile filter. Particle size was determined using a Malvern Zetasizer NanoZS (Malvern, UK). siRNA content was determined by UV absorption at 260 nm and siRNA entrapment efficiency was determined by Ribogreen assay 32. Resulting particles had a mean particle diameter of approximately 50 nm, with peak width of 20 nm, and siRNA entrapment efficiency of >95%. See also PCT/US2007/080331.
Example 3
Bone Marrow-Derived Macrophage Transfection
Murine bone marrow derived macrophages were cultured according to standard protocol (Cunnick et al., J. Immunol. Methods 311:96-105, 2006). Cells were cultured in 12-well dishes for five days in the presence of 8 ng/mL of M-CSF. The optimal siRNA to lipidoid ratio was determined for each lipidoid (a ratio of either 5 or 10 wt:wt was used). Mixtures of irrelevant control siRNA or siCD45 (SEQ ID NOs:89 and 90, above) with lipidoids were prepared as described above. siRNA-lipidoid mixtures were added to macrophage cultures at the desired concentrations for 6 hours. Media was exchanged and GFP expression was analyzed by flow cytometry five days later. The formulated CD45 siRNA were shown to effectively silence primary murine bone marrow-derived macrophages with 65% protein reduction (FIG. 2)
Example 4
CD45 as a Cellular Protein Target that Regulates Infection from a Broad Range of Pathogens
CD45 mitigates viral and bacterial infections. Genetically-modified mice with reduced expression level of CD45 were protected from B. anthracis, influenza, and Ebola (see FIG. 3). Given the ability of formulated CD45 siRNA to inhibit CD45 expression in vitro and in vivo by up to 65%, it is notable that significant protective effects against lethal Ebola challenge were seen in genetically-modified mice when CD45 expression was reduced by 11-65% (FIG. 3).
Example 5
CD45 siRNA Silenced CD45 Expression in Human Cells In Vitro
The human acute myelogenous leukemia cell line, KG-1, was cultured according to standard protocol. Cells were plated into 96 wells and then untreated or treated with CD45 siRNA-lipidoid mixtures (as outlined for FIGS. 1 and 2) at the desired concentrations for 6 hours. Media was exchanged and CD45 expression was analyzed by flow cytometry four days later. The liposomally formulated CD45 siRNA were shown to effectively silence in human cells in vitro (FIG. 4). These results are consistent with the fact that the CD45 siRNA has 100% sequence identity to human and rodent CD45 and was shown to be active in reducing murine CD45 in vitro and in vivo (Table 3; FIGS. 1 and 2).
Example 6
dsRNA Synthesis
Source of Reagents
Where the source of a reagent is not specifically given herein, such reagent may be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.
siRNA Synthesis
Single-stranded RNAs were produced by solid phase synthesis on a scale of 1 μmole using an Expedite 8909 synthesizer (Applied Biosystems, Applera Deutschland GmbH, Darmstadt, Germany) and controlled pore glass (CPG, 500A, Proligo Biochemie GmbH, Hamburg, Germany) as solid support. RNA and RNA containing 2′-O-methyl nucleotides were generated by solid phase synthesis employing the corresponding phosphoramidites and 2′-O-methyl phosphoramidites, respectively (Proligo Biochemie GmbH, Hamburg, Germany). These building blocks were incorporated at selected sites within the sequence of the oligoribonucleotide chain using standard nucleoside phosphoramidite chemistry such as described in Current protocols in nucleic acid chemistry, Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA. Phosphorothioate linkages were introduced by replacement of the iodine oxidizer solution with a solution of the Beaucage reagent (Chruachem Ltd, Glasgow, UK) in acetonitrile (1%). Further ancillary reagents were obtained from Mallinckrodt Baker (Griesheim, Germany).
Deprotection and purification of the crude oligoribonucleotides by anion exchange HPLC were carried out according to established procedures. Yields and concentrations were determined by UV absorption of a solution of the respective RNA at a wavelength of 260 nm using a spectral photometer (DU 640B, Beckman Coulter GmbH, UnterschleiBheim, Germany). Double stranded RNA was generated by mixing an equimolar solution of complementary strands in annealing buffer (20 mM sodium phosphate, pH 6.8; 100 mM sodium chloride), heated in a water bath at 85-90° C. for 3 minutes and cooled to room temperature over a period of 3-4 hours. The annealed RNA solution was stored at −20° C. until use.
For the synthesis of 3′-cholesterol-conjugated siRNAs (herein referred to as -Chol-3′), an appropriately modified solid support is used for RNA synthesis. The modified solid support is prepared as follows:
Diethyl-2-azabutane-1,4-dicarboxylate AA




A 4.7 M aqueous solution of sodium hydroxide (50 mL) is added into a stirred, ice-cooled solution of ethyl glycinate hydrochloride (32.19 g, 0.23 mole) in water (50 mL). Then, ethyl acrylate (23.1 g, 0.23 mole) is added and the mixture is stirred at room temperature until completion of the reaction is ascertained by TLC. After 19 h the solution is partitioned with dichloromethane (3×100 mL). The organic layer is dried with anhydrous sodium sulfate, filtered and evaporated. The residue is distilled to afford AA (28.8 g, 61%).
3-{Ethoxycarbonylmethyl-[6-(9H-fluoren-9-ylmethoxycarbonyl-amino)-hexanoyl]-amino}-propionic acid ethyl ester AB




Fmoc-6-amino-hexanoic acid (9.12 g, 25.83 mmol) is dissolved in dichloromethane (50 mL) and cooled with ice. Diisopropylcarbodiimde (3.25 g, 3.99 mL, 25.83 mmol) is added to the solution at 0° C. It is then followed by the addition of Diethyl-azabutane-1,4-dicarboxylate (5 g, 24.6 mmol) and dimethylamino pyridine (0.305 g, 2.5 mmol). The solution is brought to room temperature and stirred further for 6 h. Completion of the reaction is ascertained by TLC. The reaction mixture is concentrated under vacuum and ethyl acetate is added to precipitate diisopropyl urea. The suspension is filtered. The filtrate is washed with 5% aqueous hydrochloric acid, 5% sodium bicarbonate and water. The combined organic layer is dried over sodium sulfate and concentrated to give the crude product which is purified by column chromatography (50% EtOAC/Hexanes) to yield 11.87 g (88%) of AB.
3-[(6-Amino-hexanoyl)-ethoxycarbonylmethyl-amino]-propionic acid ethyl ester AC




3-{Ethoxycarbonylmethyl-[6-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoyl]-amino}-propionic acid ethyl ester AB (11.5 g, 21.3 mmol) is dissolved in 20% piperidine in dimethylformamide at 0° C. The solution is continued stifling for 1 h. The reaction mixture is concentrated under vacuum, water is added to the residue, and the product is extracted with ethyl acetate. The crude product is purified by conversion into its hydrochloride salt.
3-({6-[17-(1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}ethoxycarbonylmethyl-amino)-propionic acid ethyl ester AD




The hydrochloride salt of 3-[(6-Amino-hexanoyl)-ethoxycarbonylmethyl-amino]-propionic acid ethyl ester AC (4.7 g, 14.8 mmol) is taken up in dichloromethane. The suspension is cooled to 0° C. on ice. To the suspension diisopropylethylamine (3.87 g, 5.2 mL, 30 mmol) is added. To the resulting solution cholesteryl chloroformate (6.675 g, 14.8 mmol) is added. The reaction mixture is stirred overnight. The reaction mixture is diluted with dichloromethane and ished with 10% hydrochloric acid. The product is purified by flash chromatography (10.3 g, 92%).
1-{6-[17-(1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-4-oxo-pyrrolidine-3-carboxylic acid ethyl ester AE




Potassium t-butoxide (1.1 g, 9.8 mmol) is slurried in 30 mL of dry toluene. The mixture is cooled to 0° C. on ice and 5 g (6.6 mmol) of diester AD is added slowly with stirring within 20 mins. The temperature is kept below 5° C. during the addition. The stirring is continued for 30 mins at 0° C. and 1 mL of glacial acetic acid is added, immediately followed by 4 g of NaH2PO4—H2O in 40 mL of water The resultant mixture is extracted twice with 100 mL of dichloromethane each and the combined organic extracts are washed twice with 10 mL of phosphate buffer each, dried, and evaporated to dryness. The residue is dissolved in 60 mL of toluene, cooled to 0° C. and extracted with three 50 mL portions of cold pH 9.5 carbonate buffer. The aqueous extracts are adjusted to pH 3 with phosphoric acid, and extracted with five 40 mL portions of chloroform which are combined, dried and evaporated to dryness. The residue is purified by column chromatography using 25% ethylacetate/hexane to afford 1.9 g of b-ketoester (39%).
[6-(3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-yl)-6-oxo-hexyl]-carbamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester AF




Methanol (2 mL) is added dropwise over a period of 1 h to a refluxing mixture of b-ketoester AE (1.5 g, 2.2 mmol) and sodium borohydride (0.226 g, 6 mmol) in tetrahydrofuran (10 mL). Stirring is continued at reflux temperature for 1 h. After cooling to room temperature, 1 N HCl (12.5 mL) is added, the mixture is extracted with ethylacetate (3×40 mL). The combined ethylacetate layer is dried over anhydrous sodium sulfate and concentrated under vacuum to yield the product which is purified by column chromatography (10% MeOH/CHCl3) (89%).
(6-{3-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-pyrrolidin-1-yl}-6-oxo-hexyl)-carbamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester AG




Diol AF (1.25 gm 1.994 mmol) is dried by evaporating with pyridine (2×5 mL) in vacuo. Anhydrous pyridine (10 mL) and 4,4′-dimethoxytritylchloride (0.724 g, 2.13 mmol) are added with stifling. The reaction is carried out at room temperature overnight. The reaction is quenched by the addition of methanol. The reaction mixture is concentrated under vacuum and to the residue dichloromethane (50 mL) is added. The organic layer is washed with 1M aqueous sodium bicarbonate. The organic layer is dried over anhydrous sodium sulfate, filtered and concentrated. The residual pyridine is removed by evaporating with toluene. The crude product is purified by column chromatography (2% MeOH/Chloroform, Rf=0.5 in 5% MeOH/CHCl3) (1.75 g, 95%).
Succinic acid mono-(4-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-{6-[17-(1,5-dimethyl-hexyl)-10,13-dimethyl 2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H cyclopenta[a]phenanthren-3-yloxycarbonylamino]-hexanoyl}-pyrrolidin-3-yl) ester AH




Compound AG (1.0 g, 1.05 mmol) is mixed with succinic anhydride (0.150 g, 1.5 mmol) and DMAP (0.073 g, 0.6 mmol) and dried in a vacuum at 40° C. overnight. The mixture is dissolved in anhydrous dichloroethane (3 mL), triethylamine (0.318 g, 0.440 mL, 3.15 mmol) is added and the solution is stirred at room temperature under argon atmosphere for 16 h. It is then diluted with dichloromethane (40 mL) and washed with ice cold aqueous citric acid (5 wt %, 30 mL) and water (2×20 mL). The organic phase is dried over anhydrous sodium sulfate and concentrated to dryness. The residue is used as such for the next step.
Cholesterol derivatised CPG AI




Succinate AH (0.254 g, 0.242 mmol) is dissolved in a mixture of dichloromethane/acetonitrile (3:2, 3 mL). To that solution DMAP (0.0296 g, 0.242 mmol) in acetonitrile (1.25 mL), 2,2′-Dithio-bis(5-nitropyridine) (0.075 g, 0.242 mmol) in acetonitrile/dichloroethane (3:1, 1.25 mL) are added successively. To the resulting solution triphenylphosphine (0.064 g, 0.242 mmol) in acetonitrile (0.6 ml) is added. The reaction mixture turned bright orange in color. The solution is agitated briefly using a wrist-action shaker (5 mins). Long chain alkyl amine-CPG (LCAA-CPG) (1.5 g, 61 mM) is added. The suspension is agitated for 2 h. The CPG is filtered through a sintered funnel and washed with acetonitrile, dichloromethane and ether successively. Unreacted amino groups are masked using acetic anhydride/pyridine. The achieved loading of the CPG is measured by taking UV measurement (37 mM/g).
The synthesis of siRNAs bearing a 5′-12-dodecanoic acid bisdecylamide group (herein referred to as “5′-C32-”) or a 5′-cholesteryl derivative group (herein referred to as “5′-Chol-”) is performed as described in WO 2004/065601, except that, for the cholesteryl derivative, the oxidation step is performed using the Beaucage reagent in order to introduce a phosphorothioate linkage at the 5′-end of the nucleic acid oligomer.
Other embodiments are in the claims.

## Claims

1. A double-stranded ribonucleic acid (dsRNA), wherein said dsRNA comprises a sense strand and an antisense strand that are substantially complementary to each other, and wherein said antisense strand comprises a region that is substantially complementary to a corresponding region less than 30 nucleotides in length of an mRNA encoding CD45, and wherein said antisense strand comprises at least 15 contiguous nucleotides of SEQ ID NO:148, and wherein said dsRNA targets cleavage of the CD45 mRNA.

2. The dsRNA of claim 1, wherein said dsRNA, upon contact with a cell expressing said CD45 gene, inhibits expression of said CD45 gene by at least 20% as compared to a control cell expressing said CD45 gene and not in contact with said dsRNA.

3. The dsRNA of claim 1, wherein at least one strand of said dsRNA comprises at least one modified nucleotide.

4. The dsRNA of claim 3, wherein said modified nucleotide is chosen from the group consisting of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

5. The dsRNA of claim 3, wherein said modified nucleotide is chosen from the group consisting of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

6. The dsRNA of claim 1, wherein said sense strand and said antisense strand form a region of complementarity and said region of complementarity is at least 15 nucleotides in length.

7. The dsRNA of claim 6, wherein said region of complementarity is 19-24 nucleotides in length.

8. The dsRNA of claim 1, wherein said dsRNA, upon contact with a cell expressing CD45, inhibits expression of CD45 by at least 20% as measured in the P388D1 cell assay as compared to a control cell expressing CD45 and not in contact with said dsRNA.

9. A cell comprising the dsRNA of claim 1.

10. A pharmaceutical composition comprising the dsRNA of claim 1, and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, wherein said dsRNA, upon contact with a cell expressing said CD45 gene, inhibits expression of said CD45 gene by at least 20%, as measured in a P388D1 cell assay as compared to a control cell expressing CD45 and not in contact with said dsRNA.

12. A method for inhibiting expression of a CD45 gene in a cell, the method comprising:
(a) introducing into the cell the dsRNA of claim 1; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the CD45 gene, thereby inhibiting expression of the CD45 gene in the cell.

13. The method of claim 12, wherein the cell produced in step (a) is maintained for a time sufficient to inhibit expression of CD45 by 20% as compared to a control cell expressing CD45 into which said dsRNA has not been introduced.

14. A vector for inhibiting the expression of the CD45 gene in a cell, said vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes at least one strand of the dsRNA of claim 1.

15. A cell comprising the vector of claim 14.

16. The dsRNA of claim 1, wherein said sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO: 147.

17. The dsRNA of claim 1, wherein said antisense strand comprises SEQ ID NO: 148.

18. The dsRNA of claim 1, wherein the sense strand comprises SEQ ID NO:147 and the antisense strand comprises SEQ ID NO:148.

19. The dsRNA of claim 1, wherein the sense strand comprises SEQ ID NO:243 and the antisense strand comprises SEQ ID NO:244.

20. The dsRNA of claim 1, wherein the sense strand consists of SEQ ID NO:1 (GAAuAAAAAccGuuAuGuuTsT) and the antisense strand consists of SEQ ID NO:2 (AAcAuAACGGUUUUuAUUCTsT) and each strand includes a 2′-O-methyl ribonucleotide as indicated by a lower case letter “c” or “u” and a phosphorothioate as indicated by a lower case letter “s”.

21. The dsRNA of claim 19, wherein at least one strand comprises at least one 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, or a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

22. A method for inhibiting expression of a CD45 gene in a cell, the method comprising:
(a) introducing into the cell the dsRNA of claim 20; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the CD45 gene, thereby inhibiting expression of the CD45 gene in the cell.

23. A pharmaceutical composition comprising the dsRNA of claim 20 and a pharmaceutically acceptable carrier.